William Boden | Profiles RNS

William Boden, MD

Professor

Boston University Chobanian & Avedisian School of Medicine

Medicine

Cardiovascular Medicine

MD, State University of New York at Brockport
BS, Le Moyne College

Websites

	MAVERIC
	ResearchGate
	BUSM
	BUMC
	Harvard Catalyst

I am ABIM board-certified in both Internal Medicine and the subspecialty of Cardiovascular Disease. Since 1979, I have held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and Albany Medical College. For the past 27 consecutive years, I have held leadership roles as either a Chief of cardiology or Chief of Medicine at both federal VA facilities and in the academic private sector, all of which have had strong affiliations with their respective academic health centers. In 2016, I re-joined the VA Boston MAVERIC Center as the Scientific Director, Clinical Trials Network, for the VA New England Healthcare System, and as the Research Lead Physician, for VISN 1.

I have extensive prior experience in clinical trials and comparative effectiveness research, and have served in a leadership capacity in several important national and international clinical trials, including as Study Chair for VA CSP-funded VANQWISH and COURAGE Trials, as Study Co-Chair of the NIH-funded AIM-HIGH Trial, and as a national co-PI for the NIH-funded ISCHEMIA Trial. My principal research interests include studies in stable ischemic heart disease, post-MI secondary prevention, acute coronary syndromes, and preventive cardiology.

Lecturer in Medicine
Harvard Medical School

Physician Research Lead & Scientific Director
VA Boston Healthcare System
MAVERIC Center
Clinical Trials Network

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Kaski JC, Al-Lamee R, Boden WE. The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease. Eur Heart J. 2024 Apr 07; 45(14):1201-1204. PMID: 38442290

Reynolds HR, Cyr DD, Merz CNB, Shaw LJ, Chaitman BR, Boden WE, Alexander KP, Rosenberg YD, Bangalore S, Stone GW, Held C, Spertus J, Goetschalckx K, Bockeria O, Newman JD, Berger JS, Elghamaz A, Lopes RD, Min JK, Berman DS, Picard MH, Kwong RY, Harrington RA, Thomas B, O'Brien SM, Maron DJ, Hochman JS. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial. J Am Heart Assoc. 2024 Mar 05; 13(5):e029850. PMID: 38410945

Gaba P, Bhatt DL, Boden WE. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use. Eur Heart J. 2024 Feb 07; 45(6):439-442. PMID: 37889071; PMCID: PMC10849332; DOI: 10.1093/eurheartj/ehad668;

Gaudino M, Flather M, Capodanno D, Milojevic M, Bhatt DL, Biondi Zoccai G, Boden WE, Devereaux PJ, Doenst T, Farkouh M, Freemantle N, Fremes S, Puskas J, Landoni G, Lawton J, Myers PO, Redfors B, Sandner S. European Association of Cardio-Thoracic Surgery (EACTS) expert consensus statement on perioperative myocardial infarction after cardiac surgery. Eur J Cardiothorac Surg. 2024 Feb 01; 65(2). PMID: 38420786

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 Jan 02; 13(1):e032413. PMID: 38156550; PMCID: PMC10863822; DOI: 10.1161/JAHA.123.032413;

Gulati M, Michos ED, Boden WE, Guyton JR. JCL roundtable: Evolution of preventive cardiology and clinical lipidology. J Clin Lipidol. 2024; 18(1):e10-e20. PMID: 38245457

Boden WE. Optimal medical therapy vs revascularization in chronic coronary syndromes: Does ISCHEMIA move the needle toward or away from revascularization?? Vascul Pharmacol. 2024 Mar; 154:107253. PMID: 38070758

Yuyun MF, Joseph J, Erqou SA, Kinlay S, Echouffo-Tcheugui JB, Peralta AO, Hoffmeister PS, Boden WE, Yarmohammadi H, Martin DT, Singh JP. Persistence of significant secondary mitral regurgitation post-cardiac resynchronization therapy and survival: a systematic review and meta-analysis : Mitral regurgitation and mortality post-CRT. Heart Fail Rev. 2024 Jan; 29(1):165-178.View Related Profiles.

Peralta, Adelqui
Joseph, Jacob
Yuyun, Matthew
Hoffmeister, Peter
Kinlay, Scott
Boden, William

PMID: 37855988

Weintraub WS, Boden WE. Can we measurably improve the prediction of recurrent coronary artery disease events? Eur Heart J. 2023 Sep 21; 44(36):3466-3468. PMID: 37738645

Barili F, Anselmi A, Boden WE, Sousa Uva M, Parolari A. Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial. J Am Coll Cardiol. 2023 Sep 19; 82(12):e101. PMID: 37704317

Showing 10 of 395 results. Show More

Mavromatis K, Jones PG, Ali ZA, Stone GW, Rhodes GM, Bangalore S, O'Brien S, Genereux P, Horst J, Dressler O, Goodman S, Alexander K, Mathew A, Chen J, Bhargava B, Uxa A, Boden WE, Mark DB, Reynolds HR, Maron DJ, Hochman JS, Spertus JA. Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial. J Am Coll Cardiol. 2023 Jul 25; 82(4):295-313. PMID: 37468185; PMCID: PMC10551823; DOI: 10.1016/j.jacc.2023.05.025;

Stone GW, Ali ZA, O'Brien SM, Rhodes G, Genereux P, Bangalore S, Mavromatis K, Horst J, Dressler O, Poh KK, Nath RK, Moorthy N, Witkowski A, Dwivedi SK, Bockeria O, Chen J, Smanio PEP, Picard MH, Chaitman BR, Berman DS, Shaw LJ, Boden WE, White HD, Fremes SE, Rosenberg Y, Reynolds HR, Spertus JA, Hochman JS, Maron DJ. Impact of Complete Revascularization in the ISCHEMIA Trial. J Am Coll Cardiol. 2023 Sep 19; 82(12):1175-1188. PMID: 37462593; PMCID: PMC10529674; DOI: 10.1016/j.jacc.2023.06.015;

Aggarwal R, Chiu N, Libby P, Boden WE, Bhatt DL. Low-Density Lipoprotein Cholesterol Levels in Adults With Coronary Artery Disease in the US, January 2015 to March 2020. JAMA. 2023 Jul 03; 330(1):80-82. PMID: 37395777; PMCID: PMC10318472; DOI: 10.1001/jama.2023.8646;

Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jul 13; 389(2):107-117. PMID: 37326322

Boden WE, Kaski JC, Berry C. Reprising Heberden's description of angina pectoris after 250 years. Eur Heart J. 2023 May 14; 44(19):1684-1686. PMID: 36515090

Nguyen DD, Spertus JA, Alexander KP, Newman JD, Dodson JA, Jones PG, Stevens SR, O'Brien SM, Gamma R, Perna GP, Garg P, Vitola JV, Chow BJW, Vertes A, White HD, Smanio PEP, Senior R, Held C, Li J, Boden WE, Mark DB, Reynolds HR, Bangalore S, Chan PS, Stone GW, Arnold SV, Maron DJ, Hochman JS. Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease: The ISCHEMIA Trial. J Am Coll Cardiol. 2023 May 02; 81(17):1697-1709. PMID: 37100486; PMCID: PMC10902923; DOI: 10.1016/j.jacc.2023.02.048;

Ostrominski JW, Boden WE. Defining the optimal approach to revascularization in chronic coronary syndrome patients with diabetes and multivessel disease: Is our equipoise evidence-based? Int J Cardiol Heart Vasc. 2023 Jun; 46:101200. PMID: 37255859; PMCID: PMC10225619; DOI: 10.1016/j.ijcha.2023.101200;

Liga R, Colli A, Taggart DP, Boden WE, De Caterina R. Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How. J Am Heart Assoc. 2023 Mar 21; 12(6):e026943. PMID: 36892041; PMCID: PMC10111551; DOI: 10.1161/JAHA.122.026943;

Price S, Kaski JC, Al-Lamee R, Boden WE, Huber K, Katz JN, Krychtiuk K. The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease. Eur Heart J. 2023 Feb 07; 44(6):445-447. PMID: 36587938

Boden WE, Marzilli M, Crea F, Mancini GBJ, Weintraub WS, Taqueti VR, Pepine CJ, Escaned J, Al-Lamee R, Gowdak LHW, Berry C, Kaski JC. Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 Feb 07; 81(5):505-514. PMID: 36725179; PMCID: PMC10561495; DOI: 10.1016/j.jacc.2022.08.814;

Stone PH, Libby P, Boden WE. Fundamental Pathobiology of Coronary Atherosclerosis and Clinical Implications for Chronic Ischemic Heart Disease Management-The Plaque Hypothesis: A Narrative Review. JAMA Cardiol. 2023 Feb 01; 8(2):192-201. PMID: 36515941

Tsao AL, Boden WE. Chronic Total Occlusion PCI and Optimal Medical Therapy: Are We Still Putting the Cart Before the Horse? Circ Cardiovasc Qual Outcomes. 2023 Mar; 16(3):e009604. PMID: 36722335

Weintraub WS, Mancini GBJ, Boden WE. Percutaneous coronary intervention from COURAGE to ISCHEMIA and beyond. Int J Cardiol. 2023 Feb 15; 373:39-43. PMID: 36427605

Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracon R, López-Sendón J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023 Jan 03; 147(1):8-19. PMID: 36335918; PMCID: PMC9797439; DOI: 10.1161/CIRCULATIONAHA.122.062714;

Leatherman S, Ferguson R, Hau C, Harrington K, Granowitz C, Philip S, Toth PP, Bhatt D, Boden W. Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins. Front Cardiovasc Med. 2022; 9:982815.View Related Profiles.

Harrington, Kelly M
Ferguson, Ryan
Leatherman, Sarah
Boden, William

PMID: 36407462; PMCID: PMC9673755; DOI: 10.3389/fcvm.2022.982815;

Boden WE, Stone PH. Lessons Learned from the ISCHEMIA Trial for the Management of Patients with Stable Ischemic Heart Disease. Annu Rev Med. 2023 Jan 27; 74:189-198. PMID: 36318679

Mavromatis K, Boden WE, Maron DJ, Mancini GBJ, Weintraub WS, Gosselin G, Berman DS, Shaw LJ, Spertus JA, Hochman JS. Comparison of Outcomes of Invasive or Conservative Management of Chronic Coronary Disease in Four Randomized Controlled Trials. Am J Cardiol. 2022 Dec 15; 185:18-28. PMID: 36257844

Reynolds HR, Diaz A, Cyr DD, Shaw LJ, Mancini GBJ, Leipsic J, Budoff MJ, Min JK, Hague CJ, Berman DS, Chaitman BR, Picard MH, Hayes SW, Scherrer-Crosbie M, Kwong RY, Lopes RD, Senior R, Dwivedi SK, Miller TD, Chow BJW, de Silva R, Stone GW, Boden WE, Bangalore S, O'Brien SM, Hochman JS, Maron DJ. Ischemia With Nonobstructive Coronary Arteries: Insights From the ISCHEMIA Trial. JACC Cardiovasc Imaging. 2023 Jan; 16(1):63-74. PMID: 36115814; PMCID: PMC9878463; DOI: 10.1016/j.jcmg.2022.06.015;

Andersson C, Schou M, Boden WE, Schwartz B, Joseph J, Fosbøl E, Køber L, Gislason GH, Torp-Pedersen C. Trends in Ischemic Evaluation in New-Onset Heart Failure Without Known Coronary Artery Disease. JACC Heart Fail. 2022 Nov; 10(11):807-815.View Related Profiles.

Schwartz, Brian
Boden, William

PMID: 36328647

Garcia RA, Spertus JA, Benton MC, Jones PG, Mark DB, Newman JD, Bangalore S, Boden WE, Stone GW, Reynolds HR, Hochman JS, Maron DJ. Association of Medication Adherence With Health Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2022 Aug 23; 80(8):755-765. PMID: 35981820; PMCID: PMC10548342; DOI: 10.1016/j.jacc.2022.05.045;

Parolari A, Almeida RMS, Boden WE. The sounds of silence. Eur Heart J. 2022 Aug 14; 43(31):2997. PMID: 35765982

Bangalore S, Hochman JS, Stevens SR, Jones PG, Spertus JA, O'Brien SM, Reynolds HR, Boden WE, Fleg JL, Williams DO, Stone GW, Sidhu MS, Mathew RO, Chertow GM, Maron DJ. Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. JAMA Cardiol. 2022 Aug 01; 7(8):825-835. PMID: 35767253; PMCID: PMC9244774; DOI: 10.1001/jamacardio.2022.1763;

Smilowitz NR, Carey EP, Shah B, Hartigan PM, Plomondon ME, Maron DJ, Maddox TM, Spertus JA, Mancini GBJ, Chaitman BR, Weintraub WS, Sedlis SP, Boden WE. Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Am J Cardiol. 2022 Oct 01; 180:1-9. PMID: 35918234; PMCID: PMC10019948; DOI: 10.1016/j.amjcard.2022.06.049;

Boden WE, Kaski JC. Evolving Roles of Optimal Medical Therapy and PCI in Chronic Coronary Syndrome Patients with Stable Angina: Introduction. Cardiovasc Drugs Ther. 2022 10; 36(5):1005-1009. PMID: 35852661

Gaba P, Bhatt DL, Mason RP, Miller M, Verma S, Steg PG, Boden WE. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. J Clin Lipidol. 2022 Jul-Aug; 16(4):389-402. PMID: 35773147

Boden WE, Andersson C. Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients. J Am Coll Cardiol. 2022 May 03; 79(17):1672-1674. PMID: 35483754

Bangalore S, Spertus JA, Stevens SR, Jones PG, Mancini GBJ, Leipsic J, Reynolds HR, Budoff MJ, Hague CJ, Min JK, Boden WE, O'Brien SM, Harrington RA, Berger JS, Senior R, Peteiro J, Pandit N, Bershtein L, de Belder MA, Szwed H, Doerr R, Monti L, Alfakih K, Hochman JS, Maron DJ. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. Circ Cardiovasc Interv. 2022 Apr; 15(4):e010925. PMID: 35411785

Shah R, Nayyar M, Le FK, Labroo A, Nasr A, Rashid A, Davis DA, Weintraub WS, Boden WE. A meta-analysis of optimal medical therapy with or without percutaneous coronary intervention in patients with stable coronary artery disease. Coron Artery Dis. 2022 03 01; 33(2):91-97. PMID: 33878073

Senior R, Reynolds HR, Min JK, Berman DS, Picard MH, Chaitman BR, Shaw LJ, Page CB, Govindan SC, Lopez-Sendon J, Peteiro J, Wander GS, Drozdz J, Marin-Neto J, Selvanayagam JB, Newman JD, Thuaire C, Christopher J, Jang JJ, Kwong RY, Bangalore S, Stone GW, O'Brien SM, Boden WE, Maron DJ, Hochman JS. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. J Am Coll Cardiol. 2022 02 22; 79(7):651-661. PMID: 35177194; PMCID: PMC8875308; DOI: 10.1016/j.jacc.2021.11.052;

Sidhu MS, Alexander KP, Huang Z, O'Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, Maron DJ. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. Am Heart J. 2022 Jun; 248:72-83. PMID: 35149037; PMCID: PMC9310436; DOI: 10.1016/j.ahj.2022.01.017;

De Caterina R, Liga R, Boden WE. Myocardial revascularization in ischaemic cardiomyopathy: routine practice vs. scientific evidence. Eur Heart J. 2022 02 03; 43(5):387-390. PMID: 34633040

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172. PMID: 35157055; PMCID: PMC8844997; DOI: 10.1001/jamanetworkopen.2021.48172;

Lopez-Sendon JL, Cyr DD, Mark DB, Bangalore S, Huang Z, White HD, Alexander KP, Li J, Nair RG, Demkow M, Peteiro J, Wander GS, Demchenko EA, Gamma R, Gadkari M, Poh KK, Nageh T, Stone PH, Keltai M, Sidhu M, Newman JD, Boden WE, Reynolds HR, Chaitman BR, Hochman JS, Maron DJ, O'Brien SM. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. Eur Heart J. 2022 01 13; 43(2):148-149. PMID: 34514494

Boden WE, Kaski JC, Al-Lamee R, Weintraub WS. What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation? Lancet. 2022 02 12; 399(10325):691-694. PMID: 35033221

Boden WE, De Caterina R, Taggart DP. Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. Eur Heart J. 2021 12 28; 43(1):68-70. PMID: 34405227

Bhasin S, Lincoff AM, Basaria S, Bauer DC, Boden WE, Cunningham GR, Davey D, Dubcenco E, Fukumoto S, Garcia M, Granger CB, Kalahasti V, Khera M, Miller MG, Mitchell LM, O'Leary MP, Pencina KM, Snyder PJ, Thompson IM, Travison TG, Wolski K, Nissen SE. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 03; 245:41-50. PMID: 34871580

Brown DL, Boden WE. Impact of revascularisation on outcomes in chronic coronary syndromes: a new meta-analysis with the same old biases? Eur Heart J. 2021 12 01; 42(45):4652-4655. PMID: 34110408

Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Budoff M, Preston Mason R, Tardif JC, Boden WE, Ballantyne CM. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021 11 30; 144(22):1750-1759. PMID: 34706555; PMCID: PMC8614567; DOI: 10.1161/CIRCULATIONAHA.121.055560;

Pelliccia F, Marzilli M, Boden WE, Camici PG. Why the Term MINOCA Does Not Provide Conceptual Clarity for Actionable Decision-Making in Patients with Myocardial Infarction with No Obstructive Coronary Artery Disease. J Clin Med. 2021 Oct 09; 10(20). PMID: 34682754; PMCID: PMC8538927; DOI: 10.3390/jcm10204630;

Merz CNB, Beltrame JF, Berry C, Boden WE, Camici PG, Crea F, Hochman JS, Kaski JC, O'Gara PT, Ong P, Pepine CJ, Shimokawa H, Sechtem U, Stone GW. Insights to advance our management of myocardial ischemia: From obstructive epicardial disease to functional coronary alterations. Am Heart J Plus. 2021 Nov; 11:100060. PMID: 38559316; PMCID: PMC10978135; DOI: 10.1016/j.ahjo.2021.100060;

Arbab-Zadeh A, Zeger SL, Blumenthal RS, Weintraub WS, Boden WE. The Rising Urgency to Pivot Back Toward Hippocratic Medicine. Am J Med. 2022 01; 135(1):49-52. PMID: 34610297

Newman JD, Anthopolos R, Mancini GBJ, Bangalore S, Reynolds HR, Kunichoff DF, Senior R, Peteiro J, Bhargava B, Garg P, Escobedo J, Doerr R, Mazurek T, Gonzalez-Juanatey J, Gajos G, Briguori C, Cheng H, Vertes A, Mahajan S, Guzman LA, Keltai M, Maggioni AP, Stone GW, Berger JS, Rosenberg YD, Boden WE, Chaitman BR, Fleg JL, Hochman JS, Maron DJ. Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation. 2021 10 26; 144(17):1380-1395. PMID: 34521217; PMCID: PMC8545918; DOI: 10.1161/CIRCULATIONAHA.121.054439;

White HD, O'Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA Cardiol. 2021 09 01; 6(9):1023-1031. PMID: 33938917; PMCID: PMC8094032; DOI: 10.1001/jamacardio.2021.1651;

Manolis AJ, Boden WE, Collins P, Dechend R, Kallistratos MS, Lopez Sendon J, Poulimenos LE, Ambrosio G, Rosano G. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med. 2021 Oct; 92:40-47. PMID: 34419311

Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, Miller M, Michos ED, Ballantyne CM, Boden WE, Bhatt DL. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021 Aug; 38:100997. PMID: 34505026; PMCID: PMC8413259; DOI: 10.1016/j.eclinm.2021.100997;

Boden WE, Gersh BJ. Defining the Proper SYNTAX for Long-Term Benefit of Myocardial Revascularization With Optimal Medical Therapy. J Am Coll Cardiol. 2021 07 06; 78(1):39-41. PMID: 34210412

Boden WE. RESPONSE: The Exit Interview-of a Professional Lifetime. J Am Coll Cardiol. 2021 05 04; 77(17):2256-2257. PMID: 33926662

Gersh BJ, Boden WE, Bhatt DL, Stone PH, Crea F, Lüscher TF. To stent or not to stent? Treating angina after ISCHEMIA-introduction. Eur Heart J. 2021 04 07; 42(14):1387-1388. PMID: 33827136

Boden WE, Stone PH. To stent or not to stent? Treating angina after ISCHEMIA-why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial. Eur Heart J. 2021 04 07; 42(14):1394-1400. PMID: 33827137

Handberg EM, Merz CNB, Cooper-Dehoff RM, Wei J, Conlon M, Lo MC, Boden W, Frayne SM, Villines T, Spertus JA, Weintraub W, O'Malley P, Chaitman B, Shaw LJ, Budoff M, Rogatko A, Pepine CJ. Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J. 2021 07; 237:90-103. PMID: 33745898

McCreanor V, Nowbar A, Rajkumar C, Barnett AG, Francis D, Graves N, Boden WE, Weintraub WS, Al-Lamee R, Parsonage WA. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial. BMJ Open. 2021 02 09; 11(2):e044054. PMID: 33563623; PMCID: PMC7875263; DOI: 10.1136/bmjopen-2020-044054;

Bossard M, Gao P, Boden W, Steg G, Tanguay JF, Joyner C, Granger CB, Kastrati A, Faxon D, Budaj A, Pais P, Di Pasquale G, Valentin V, Flather M, Moccetti T, Yusuf S, Mehta SR. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021 11; 107(21):1739-1747. PMID: 33504513

Soares A, Boden WE, Hueb W, Brooks MM, Vlachos HEA, O'Fee K, Hardi A, Brown DL. Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials. J Am Heart Assoc. 2021 01 19; 10(2):e019114. PMID: 33442990; PMCID: PMC7955292; DOI: 10.1161/JAHA.120.019114;

Boden WE, Bhatt DL. Translating the findings of ISCHEMIA into clinical practice: a challenging START. EuroIntervention. 2020 Dec 18; 16(12):e953-e956. PMID: 33337322

Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation. 2021 02 23; 143(8):790-804. PMID: 33267610; PMCID: PMC7902479; DOI: 10.1161/CIRCULATIONAHA.120.047987;

Ferraro R, Latina JM, Alfaddagh A, Michos ED, Blaha MJ, Jones SR, Sharma G, Trost JC, Boden WE, Weintraub WS, Lima JAC, Blumenthal RS, Fuster V, Arbab-Zadeh A. Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 11 10; 76(19):2252-2266. PMID: 33153586

Farkouh ME, Godoy LC, Brooks MM, Mancini GBJ, Vlachos H, Bittner VA, Chaitman BR, Siami FS, Hartigan PM, Frye RL, Boden WE, Fuster V. Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. J Am Coll Cardiol. 2020 11 10; 76(19):2197-2207. PMID: 33153578

Mavromatis K, Boden WE. What is the Real Message of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) Trial for Academic and Practising Cardiologists? Eur Cardiol. 2020 Feb; 15:e64. PMID: 33042227; PMCID: PMC7539144; DOI: 10.15420/ecr.2020.26;

Boden WE, Baum S, Toth PP, Fazio S, Bhatt DL. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. Future Cardiol. 2021 01; 17(1):155-174. PMID: 32959713

Boden WE, Burke GM. Will REFINE Resurrect the "Ischemia Hypothesis"? JACC Cardiovasc Imaging. 2021 03; 14(3):654-656.View Related Profiles.

Burke, Gordon
Boden, William

PMID: 32828767

Radaideh Q, Osman M, Kheiri B, Al-Abdouh A, Barbarawi M, Bachuwa G, Tamis-Holland JE, Shammas NW, Boden WE. Meta-Analysis of the Effect of Percutaneous Coronary Intervention on Death and Myocardial Infarction in Patients With Stable Coronary Artery Disease and Inducible Myocardial Ischemia. Am J Cardiol. 2020 10 15; 133:171-174. PMID: 32838929

Weintraub WS, Boden WE. Deferral of PCI, a safe strategy in diabetic patients with chronic coronary syndromes. Heart. 2020 11; 106(21):1627-1628. PMID: 32723758

Branch-Elliman W, Lehmann LS, Boden WE, Ferguson R, Monach P. Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age? Contemp Clin Trials Commun. 2020 Sep; 19:100614.View Related Profiles.

Branch-Elliman, Westyn
Boden, William

PMID: 32724866; PMCID: PMC7366075; DOI: 10.1016/j.conctc.2020.100614;

Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, Picard MH, Kwong RY, Bairey-Merz CN, Cyr DD, Lopes RD, Lopez-Sendon JL, Held C, Szwed H, Senior R, Gosselin G, Nair RG, Elghamaz A, Bockeria O, Chen J, Chernyavskiy AM, Bhargava B, Newman JD, Hinic SB, Jaroch J, Hoye A, Berger J, Boden WE, O'Brien SM, Maron DJ, Hochman JS. Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia: Secondary Analysis of the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2020 07 01; 5(7):773-786. PMID: 32227128; PMCID: PMC7105951; DOI: 10.1001/jamacardio.2020.0822;

Boden WE, Bhatt DL, Toth PP, Ray KK, Chapman MJ, Lüscher TF. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020 06 21; 41(24):2304-2312. PMID: 31872245; PMCID: PMC7308541; DOI: 10.1093/eurheartj/ehz778;

Boden WE, Hartigan PM, Mancini J, Teo KK, Chaitman BR, Maron DJ, Kostuk WJ, Hartigan JA, Dada M, Spertus JA, Bates ER, Weintraub WS. Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. Am J Cardiol. 2020 09 01; 130:1-6. PMID: 32654755

Weintraub WS, Boden WE. PCSK9 Inhibition for Therapeutic Decision-Making: Assessing the Value. J Am Coll Cardiol. 2020 05 12; 75(18):2309-2311. PMID: 32381161

Marzilli M, Crea F, Morrone D, Bonow RO, Brown DL, Camici PG, Chilian WM, DeMaria A, Guarini G, Huqi A, Merz CNB, Pepine C, Scali MC, Weintraub WS, Boden WE. Myocardial ischemia: From disease to syndrome. Int J Cardiol. 2020 09 01; 314:32-35. PMID: 32348810

Boden WE. Letter by Boden Regarding Article, "Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials". Circ Cardiovasc Qual Outcomes. 2020 04; 13(4):e006632. PMID: 32283968

Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold FW, Broderick S, Ferguson TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1395-1407. PMID: 32227755; PMCID: PMC7263833; DOI: 10.1056/NEJMoa1915922;

Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon R, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS. Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med. 2020 04 23; 382(17):1608-1618. PMID: 32227756; PMCID: PMC7274537; DOI: 10.1056/NEJMoa1915925;

Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman JS, Mark DB. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med. 2020 04 09; 382(15):1408-1419. PMID: 32227753; PMCID: PMC7261489; DOI: 10.1056/NEJMoa1916370;

Boden WE, Miller MG, McBride R, Harvey C, Snabes MC, Schmidt J, McGovern ME, Fleg JL, Desvigne-Nickens P, Anderson T, Kashyap M, Probstfield JL. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. Am Heart J. 2020 06; 224:65-76. PMID: 32335402

Boden WE, Mancini GBJ. The Two-Edged Sword of Shared Clinical Decision-Making in the Post-ISCHEMIA World of Stable Coronary Artery Disease Management: Clinical Commentary on "It Happened So Fast … I Guess, Yes, I Was Lucky". Circ Cardiovasc Qual Outcomes. 2020 02; 13(2):e006451. PMID: 32063039

Mancini GBJ, Boden WE. Diagnostic Implications in the Aftermath of the ISCHEMIA Trial. Am J Cardiol. 2020 05 01; 125(9):1438-1440. PMID: 32145898

De Caterina R, Boden WE. The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes - A call to action. Int J Cardiol. 2020 04 01; 304:5-7. PMID: 31982164

Newman JD, Alexander KP, Gu X, O'Brien SM, Boden WE, Govindan SC, Senior R, Moorthy N, Rezende PC, Demkow M, Lopez-Sendon JL, Bockeria O, Pandit N, Gosselin G, Stone PH, Spertus JA, Stone GW, Fleg JL, Hochman JS, Maron DJ. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e006002. PMID: 31718297; PMCID: PMC7157834; DOI: 10.1161/CIRCOUTCOMES.119.006002;

Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin M, Haas M, Lindström S, Assimes TL, Huang J, Min Lee K, Shao Q, Huffman JE, Kabrhel C, Huang Y, Sun YV, Vujkovic M, Saleheen D, Miller DR, Reaven P, DuVall S, Boden WE, Pyarajan S, Reiner AP, Trégouët DA, Henke P, Kooperberg C, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, Smith NL, O'Donnell CJ, Tsao PS, Kathiresan S, Obi A, Damrauer SM, Natarajan P. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019 11; 51(11):1574-1579.View Related Profiles.

O'Donnell, Christopher
Gaziano, J. Michael
Boden, William

PMID: 31676865; PMCID: PMC6858581; DOI: 10.1038/s41588-019-0519-3;

Marquis-Gravel G, Roe MT, Turakhia MP, Boden W, Temple R, Sharma A, Hirshberg B, Slater P, Craft N, Stockbridge N, McDowell B, Waldstreicher J, Bourla A, Bansilal S, Wong JL, Meunier C, Kassahun H, Coran P, Bataille L, Patrick-Lake B, Hirsch B, Reites J, Mehta R, Muse ED, Chandross KJ, Silverstein JC, Silcox C, Overhage JM, Califf RM, Peterson ED. Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation. Circulation. 2019 10 22; 140(17):1426-1436. PMID: 31634011

Koutroumpakis E, Gosmanova EO, Stahura H, Jou S, Alreshq R, Ata A, Sidhu MS, Philbin E, Boden WE, Lyubarova R. Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease. Cardiovasc Drugs Ther. 2019 08; 33(4):443-451. PMID: 31123935

Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao Q, Huffman JE, Natarajan P, Arya S, Small A, Sun YV, Vujkovic M, Freiberg MS, Wang L, Chen J, Saleheen D, Lee JS, Miller DR, Reaven P, Alba PR, Patterson OV, DuVall SL, Boden WE, Beckman JA, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, O'Donnell CJ, Kathiresan S, Tsao PS, Damrauer SM. Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat Med. 2019 08; 25(8):1274-1279.View Related Profiles.

O'Donnell, Christopher
Gaziano, J. Michael
Boden, William

PMID: 31285632; PMCID: PMC6768096; DOI: 10.1038/s41591-019-0492-5;

Lyubarova R, Albers JJ, Marcovina SM, Yao Y, McBride R, Topliceanu A, Anderson T, Fleg JL, Desvigne-Nickens P, Kashyap ML, McGovern ME, Boden WE. Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial. J Cardiovasc Pharmacol Ther. 2019 11; 24(6):534-541. PMID: 31131629

Mancini GBJ, Maron DJ, Hartigan PM, Spertus JA, Kostuk WJ, Berman DS, Teo KK, Weintraub WS, Boden WE. Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. J Am Coll Cardiol. 2019 04 30; 73(16):2049-2058. PMID: 31023428

Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Alexander KP, Senior R, Boden WE, Stone GW, Goodman SG, Lopes RD, Lopez-Sendon J, White HD, Maggioni AP, Shaw LJ, Min JK, Picard MH, Berman DS, Chaitman BR, Mark DB, Spertus JA, Cyr DD, Bhargava B, Ruzyllo W, Wander GS, Chernyavskiy AM, Rosenberg YD, Maron DJ. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiol. 2019 03 01; 4(3):273-286. PMID: 30810700; PMCID: PMC6439551; DOI: 10.1001/jamacardio.2019.0014;

Rasalingam R, Boden WE. Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease. Am J Cardiol. 2019 05 15; 123(10):1729-1731.View Related Profiles.

Rasalingam, Ravi
Boden, William

PMID: 30922541

Farkouh ME, Sidhu MS, Brooks MM, Vlachos H, Boden WE, Frye RL, Hartigan P, Siami FS, Bittner VA, Chaitman BR, Mancini GBJ, Fuster V. Impact of Chronic Kidney Disease on Outcomes of Myocardial Revascularization in Patients With Diabetes. J Am Coll Cardiol. 2019 02 05; 73(4):400-411. PMID: 30704571

Wadhera RK, Sukul D, Secemsky EA, Shen C, Gurm HS, Boden WE, Yeh RW. Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. JAMA Intern Med. 2019 02 01; 179(2):259-261. PMID: 30556822; PMCID: PMC6439647; DOI: 10.1001/jamainternmed.2018.5124;

Weintraub WS, Hartigan PM, Mancini GBJ, Teo KK, Maron DJ, Spertus JA, Chaitman BR, Shaw LJ, Berman D, Boden WE. Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019 02; 12(2):e005079. PMID: 30773025

Maron DJ, Mancini GBJ, Hartigan PM, Spertus JA, Sedlis SP, Kostuk WJ, Berman DS, Teo KK, Weintraub WS, Boden WE. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. J Am Coll Cardiol. 2018 11 06; 72(19):2297-2305. PMID: 30384885

Boden WE, Bhatt DL. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? Circulation. 2018 08 28; 138(9):858-860. PMID: 30354448

Saour BM, Wang JH, Lavelle MP, Mathew RO, Sidhu MS, Boden WE, Sacco JD, Costanzo EJ, Hossain MA, Vachharanji T, Alrefaee A, Asif A. TpTe and TpTe/QT: novel markers to predict sudden cardiac death in ESRD? J Bras Nefrol. 2019 Jan-Mar; 41(1):38-47. PMID: 30118535; PMCID: PMC6534015; DOI: 10.1590/2175-8239-JBN-2017-0021;

Bangalore S, Maron DJ, Fleg JL, O'Brien SM, Herzog CA, Stone GW, Mark DB, Spertus JA, Alexander KP, Sidhu MS, Chertow GM, Boden WE, Hochman JS. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. Am Heart J. 2018 11; 205:42-52. PMID: 30172098; PMCID: PMC6283671; DOI: 10.1016/j.ahj.2018.07.023;

Probstfield JL, Boden WE, Anderson T, Branch K, Kashyap M, Fleg JL, Desvigne-Nickens P, McBride R, McGovern M. Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. J Clin Lipidol. 2018 Nov - Dec; 12(6):1413-1419. PMID: 30131256

Boden WE, Redberg RF. Evolving from volume to value, or to a bolder vision of reimbursement reform? Am Heart J. 2018 10; 204:174-177. PMID: 30146116

Mok Y, Ballew SH, Bash LD, Bhatt DL, Boden WE, Bonaca MP, Carrero JJ, Coresh J, D'Agostino RB, Elley CR, Fowkes FGR, Jee SH, Kovesdy CP, Mahaffey KW, Nadkarni G, Peterson ED, Sang Y, Matsushita K. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. J Am Heart Assoc. 2018 07 07; 7(14).View Related Profiles.

D'Agostino, Ralph
Boden, William

PMID: 29982232; PMCID: PMC6064832; DOI: 10.1161/JAHA.117.008426;

Weintraub WS, Taggart DP, Mancini GBJ, Brown DL, Boden WE. Historical Milestones in the Management of Stable Coronary Artery Disease over the Last Half Century. Am J Med. 2018 11; 131(11):1285-1292. PMID: 29959899

Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol. 2018 07 17; 72(3):330-343. PMID: 29935936

Mancini GBJ, Boden WE, Brooks MM, Vlachos H, Chaitman BR, Frye R, Bittner V, Hartigan PM, Dagenais GR. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials. Atherosclerosis. 2018 10; 277:186-194. PMID: 29861270

Zhang Z, Jones P, Weintraub WS, Mancini GBJ, Sedlis S, Maron DJ, Teo K, Hartigan P, Kostuk W, Berman D, Boden WE, Spertus JA. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e003971. PMID: 29752388

Maron DJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangalore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB, Williams DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 07; 201:124-135. PMID: 29778671; PMCID: PMC6005768; DOI: 10.1016/j.ahj.2018.04.011;

Ramadan R, Boden WE, Kinlay S. Management of Left Main Coronary Artery Disease. J Am Heart Assoc. 2018 03 31; 7(7).View Related Profiles.

Ramadan, Ronnie
Kinlay, Scott
Boden, William

PMID: 29605817; PMCID: PMC5907594; DOI: 10.1161/JAHA.117.008151;

Williams BA, Chagin KM, Bash LD, Boden WE, Duval S, Fowkes FGR, Mahaffey KW, Patel MD, D'Agostino RB, Peterson ED, Kattan MW, Bhatt DL, Bonaca MP. External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis. 2018 05; 272:80-86.View Related Profiles.

D'Agostino, Ralph
Boden, William

PMID: 29579671

Toth PP, Jones SR, Slee A, Fleg J, Marcovina SM, Lacy M, McBride R, Boden WE. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol. 2018 May - Jun; 12(3):741-747.e11. PMID: 29627296

Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol. 2018 Mar - Apr; 12(2):348-355.e2. PMID: 29409728; PMCID: PMC5931743; DOI: 10.1016/j.jacl.2018.01.002;

Lyubarova R, Boden WE, Fein SA, Schulman-Marcus J, Torosoff M. Successful percutaneous coronary intervention significantly improves coronary sinus blood flow as assessed by transthoracic echocardiography. J Echocardiogr. 2018 06; 16(2):65-71. PMID: 29116574

Schulman-Marcus J, Boden WE. Early Revascularization in NSTE-ACS: Insights From the ICTUS Long-Term Follow-Up. J Am Coll Cardiol. 2017 09 12; 70(11):1423-1424. PMID: 28882243

Weintraub WS, Boden WE. Making Cardiovascular Care More Responsive to Societal Needs. Am J Med. 2017 11; 130(11):1259-1261. PMID: 28797644

Schulman-Marcus J, Weintraub WS, Boden WE. Reconsidering the Gatekeeper Paradigm for Percutaneous Coronary Intervention in Stable Coronary Disease Management. Am J Cardiol. 2017 Oct 15; 120(8):1450-1452. PMID: 28818317; DOI: 10.1016/j.amjcard.2017.07.021;

Lyubarova R, Robinson JG, Miller M, Simmons DL, Xu P, Abramson BL, Elam MB, Brown TM, McBride R, Fleg JL, Desvigne-Nickens P, Ayenew W, Boden WE. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol. 2017 Sep - Oct; 11(5):1201-1211. PMID: 28807460; PMCID: PMC5612889; DOI: 10.1016/j.jacl.2017.06.017;

Banerjee S, Angiolillo DJ, Boden WE, Murphy JG, Khalili H, Hasan AA, Harrington RA, Rao SV. Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2017 Apr 11; 69(14):1861-1870. PMID: 28385315; DOI: 10.1016/j.jacc.2017.02.012;

Padala SK, Lavelle MP, Sidhu MS, Cabral KP, Morrone D, Boden WE, Toth PP. Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review. J Cardiovasc Pharmacol Ther. 2017 Nov; 22(6):499-510. PMID: 28361599

Boden WE, Meadows JL. Role of Imaging in the Management of Stable Ischemic Heart Disease: An Evolving Paradigm Shift. JACC Cardiovasc Imaging. 2017 03; 10(3):335-337. PMID: 28279381

Pragani MA, Desai KP, Morrone D, Sidhu MS, Boden WE. The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines. Rev Cardiovasc Med. 2017; 18(1):14-20. PMID: 28509889

Mathew RO, Bangalore S, Lavelle MP, Pellikka PA, Sidhu MS, Boden WE, Asif A. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017 Apr; 91(4):797-807. PMID: 28040264; DOI: 10.1016/j.kint.2016.09.049;

Mancini GB, Farkouh ME, Brooks MM, Chaitman BR, Boden WE, Vlachos H, Hartigan PM, Siami FS, Sidhu MS, Bittner V, Frye R, Fuster V. Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. J Am Coll Cardiol. 2016 Sep 06; 68(10):985-95. PMID: 27585501; DOI: 10.1016/j.jacc.2016.06.021;

Nappi AG, Boden WE. Should Beta-Blockers Continue to Be Used in Post-Percutaneous Coronary Intervention Patients Without Myocardial Infarction? JACC Cardiovasc Interv. 2016 08 22; 9(16):1649-51. PMID: 27539684

Weintraub WS, Boden WE. Reexamining the Efficacy and Value of Percutaneous Coronary Intervention for Patients With Stable Ischemic Heart Disease. JAMA Intern Med. 2016 08 01; 176(8):1190-4. PMID: 27380178; PMCID: PMC5656233; DOI: 10.1001/jamainternmed.2016.3071;

Mody P, Sidhu MS, Brilakis ES, Sacco JD, Banerjee S, Boden WE. Antianginal Agents for the Management of Stable Ischemic Heart Disease: A Review. Cardiol Rev. 2016 Jul-Aug; 24(4):177-89. PMID: 26274534; DOI: 10.1097/CRD.0000000000000085;

Wijeysundera HC, Sidhu MS, Bennell MC, Qiu F, Ko DT, Knudtson ML, Tu JV, Boden WE. Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy. Circ Cardiovasc Interv. 2016 Jul; 9(7). PMID: 27418612; DOI: 10.1161/CIRCINTERVENTIONS.115.003592;

Asleh R, Levy NS, Doros G, Costacou T, Robinson JG, Blum S, Goldenstein H, Boden WE, Simmons DL, Lacy MA, Grunberger G, Anderson TJ, Levy AP. Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. J Am Coll Cardiol. 2016 05 31; 67(21):2553-4. PMID: 27230052

Hagström E, Roe MT, Hafley G, Neely ML, Sidhu MS, Winters KJ, Prabhakaran D, White HD, Armstrong PW, Fox KA, Ohman EM, Boden WE. Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. Clin Cardiol. 2016 Jun; 39(6):329-37. PMID: 27177240; PMCID: PMC6490832; DOI: 10.1002/clc.22533;

Schulman-Marcus J, Boden WE. A PROMISE Fulfilled That Quality-of-Life Assessments Afford Incremental Value to Coronary Artery Disease Management. Circulation. 2016 May 24; 133(21):1989-91. PMID: 27143677; DOI: 10.1161/CIRCULATIONAHA.116.022732;

Kaul P, Ohman EM, Knight JD, Anstrom KJ, Roe MT, Boden WE, Hochman JS, Gašparovic V, Armstrong PW, McCollam P, Fakhouri W, Cowper P, Davidson-Ray L, Clapp-Channing N, White HD, Fox KA, Prabhakaran D, Mark DB. Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2016 Aug; 178:55-64. PMID: 27502852; DOI: 10.1016/j.ahj.2016.03.017;

Nappi AG, Boden WE. Does Physiology Trump Anatomy as the "Best Course" to Guide PCI Decision Making and Outcomes? J Am Coll Cardiol. 2016 Apr 12; 67(14):1712-4. PMID: 27056777; DOI: 10.1016/j.jacc.2016.01.057;

Chin CT, Boden WE, Roe MT, Neely B, Neely ML, Leiva-Pons JL, Corbalán R, Gottlieb S, Dalby AJ, Armstrong PW, Prabhakaran D, Fox KA, White HD, Ohman EM, Winters KJ, Schiele F. Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart. 2016 08 01; 102(15):1221-9. PMID: 27030601; DOI: 10.1136/heartjnl-2015-308840;

Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am J Med. 2016 Jul; 129(7):753.e13-22. PMID: 27036394; PMCID: PMC4914402; DOI: 10.1016/j.amjmed.2016.02.039;

Boden WE. A Novel Diagnostic Approach for Evaluating Suspected Coronary Artery Disease. Am J Med. 2016 Jun; 129(6):557-9. PMID: 26836388; DOI: 10.1016/j.amjmed.2016.01.023;

Boden WE, Mancini GB. CABG for Complex CAD: When Will Evidence-Based Practice Align With Evidence-Based Medicine? J Am Coll Cardiol. 2016 Jan 05; 67(1):56-8. PMID: 26764066; DOI: 10.1016/j.jacc.2015.11.004;

Cheng-Torres KA, Desai KP, Sidhu MS, Maron DJ, Boden WE. Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial? Future Cardiol. 2016 Jan; 12(1):35-44. PMID: 26696561; DOI: 10.2217/fca.15.57;

Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB, Harrington RA, Maron DJ. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016 Jan 05; 67(1):81-99. PMID: 26616030; PMCID: PMC5545795; DOI: 10.1016/j.jacc.2015.09.056;

Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med. 2015 Nov 12; 373(20):1937-46. PMID: 26559572; PMCID: PMC5656049; DOI: 10.1056/NEJMoa1505532;

Torosoff MT, Sidhu MS, Desai KP, Fein SA, Boden WE. Revascularization options in stable coronary artery disease: it is not how to revascularize, it is whether and when to revascularize. J Comp Eff Res. 2015 Sep; 4(5):505-14. PMID: 26387530; DOI: 10.2217/cer.15.37;

Boden WE. MY APPROACH to managing stable ischemic heart disease. Trends Cardiovasc Med. 2015 Nov; 25(8):753-4. PMID: 26410543; DOI: 10.1016/j.tcm.2015.05.014;

Padala SK, Sidhu MS, Hartigan PM, Maron DJ, Teo KK, Spertus JA, Mancini GB, Sedlis SP, Chaitman BR, Heller GV, Weintraub WS, Boden WE. Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial). Am J Cardiol. 2015 Nov 15; 116(10):1509-15. PMID: 26410604; PMCID: PMC5656230; DOI: 10.1016/j.amjcard.2015.08.012;

Boden WE, Padala SK, Cabral KP, Buschmann IR, Sidhu MS. Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug Des Devel Ther. 2015; 9:4793-805. PMID: 26316714; PMCID: PMC4548722; DOI: 10.2147/DDDT.S79116;

Maron DJ, Boden WE. Why Optimal Medical Therapy Should Be a Universal Standard of Care. J Am Coll Cardiol. 2015 Aug 18; 66(7):774-776. PMID: 26271058; PMCID: PMC4695209; DOI: 10.1016/j.jacc.2015.06.018;

Acharjee S, Teo KK, Jacobs AK, Hartigan PM, Barn K, Gosselin G, Tanguay JF, Maron DJ, Kostuk WJ, Chaitman BR, Mancini GB, Spertus JA, Dada MR, Bates ER, Booth DC, Weintraub WS, O'Rourke RA, Boden WE. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial. Am Heart J. 2016 Mar; 173:108-17.View Related Profiles.

Jacobs, Alice
Boden, William

PMID: 26920603; DOI: 10.1016/j.ahj.2015.07.020;

Dhamija RK, Tan H, Philbin E, Mathew RO, Sidhu MS, Wang J, Saour B, Haqqie SS, Beathard G, Yevzlin AS, Salman L, Boden WE, Siskin G, Asif A. Subcutaneous implantable cardioverter defibrillator for dialysis patients: a strategy to reduce central vein stenoses and infections. Am J Kidney Dis. 2015 Jul; 66(1):154-8. PMID: 25911316; DOI: 10.1053/j.ajkd.2015.01.028;

Bradley SM, Chan PS, Hartigan PM, Nallamothu BK, Weintraub WS, Sedlis SP, Dada M, Maron DJ, Kostuk WJ, Berman DS, Teo KK, Mancini GB, Boden WE, Spertus JA. Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial). Am J Cardiol. 2015 Jul 15; 116(2):167-73. PMID: 25960375; PMCID: PMC6572758; DOI: 10.1016/j.amjcard.2015.03.057;

Sidhu MS, Boden WE. The continued importance of optimal medical therapy with or without revascularization in diabetic patients with coronary artery disease. Trends Cardiovasc Med. 2015 Oct; 25(7):632-4. PMID: 25957809; DOI: 10.1016/j.tcm.2015.04.002;

Kalil RS, Wang JH, de Boer IH, Mathew RO, Ix JH, Asif A, Shi X, Boden WE. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int. 2015 Jun; 87(6):1250-7. PMID: 25651367; PMCID: PMC4449803; DOI: 10.1038/ki.2014.383;

Toth PP, Murthy AM, Sidhu MS, Boden WE. Is HPS2-THRIVE the death knell for niacin? J Clin Lipidol. 2015 May-Jun; 9(3):343-50. PMID: 26073392; DOI: 10.1016/j.jacl.2015.01.008;

Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. ß-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov; 7(6):872-81. PMID: 25271049; DOI: 10.1161/CIRCOUTCOMES.114.001073;

Desai KP, Sidhu MS, Boden WE. Evaluation of the stable coronary artery disease patient: anatomy trumps physiology. Trends Cardiovasc Med. 2014 Nov; 24(8):332-40. PMID: 25241252; DOI: 10.1016/j.tcm.2014.08.003;

Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014 Jul 17; 371(3):288-90. PMID: 25014706; PMCID: PMC4156937; DOI: 10.1056/NEJMc1311039;

Soukoulis V, Boden WE, Smith SC, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res. 2014 Jun 06; 114(12):1944-58. PMID: 24902977; PMCID: PMC4083844; DOI: 10.1161/CIRCRESAHA.114.302804;

Shaw LJ, Berman DS, Picard MH, Friedrich MG, Kwong RY, Stone GW, Senior R, Min JK, Hachamovitch R, Scherrer-Crosbie M, Mieres JH, Marwick TH, Phillips LM, Chaudhry FA, Pellikka PA, Slomka P, Arai AE, Iskandrian AE, Bateman TM, Heller GV, Miller TD, Nagel E, Goyal A, Borges-Neto S, Boden WE, Reynolds HR, Hochman JS, Maron DJ, Douglas PS. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging. 2014 Jun; 7(6):593-604. PMID: 24925328; PMCID: PMC4128344; DOI: 10.1016/j.jcmg.2013.10.021;

Boden WE, Franklin B, Berra K, Haskell WL, Calfas KJ, Zimmerman FH, Wenger NK. Exercise as a therapeutic intervention in patients with stable ischemic heart disease: an underfilled prescription. Am J Med. 2014 Oct; 127(10):905-11. PMID: 24844736; DOI: 10.1016/j.amjmed.2014.05.007;

Tariq SM, Sidhu MS, Toth PP, Boden WE. HDL hypothesis: where do we stand now? Curr Atheroscler Rep. 2014 Apr; 16(4):398. PMID: 24619460; DOI: 10.1007/s11883-014-0398-0;

Maron DJ, Boden WE. As REGARDS treatment goal attainment compared with COURAGE: the perfect should not be the enemy of the good. J Am Coll Cardiol. 2014 Apr 29; 63(16):1634-5. PMID: 24583302; DOI: 10.1016/j.jacc.2014.01.047;

Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014 Feb 01; 174(2):232-40. PMID: 24296791; DOI: 10.1001/jamainternmed.2013.12855;

Mancini GBJ, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. JACC Cardiovasc Interv. 2014 Feb; 7(2):195-201. PMID: 24440015; DOI: 10.1016/j.jcin.2013.10.017;

Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther. 2014 Mar; 19(2):141-58. PMID: 24363242; DOI: 10.1177/1074248413514481;

Sidhu MS, Saour BM, Boden WE. A TACTful reappraisal of chelation therapy in cardiovascular disease. Nat Rev Cardiol. 2014 Mar; 11(3):180-3. PMID: 24343569; DOI: 10.1038/nrcardio.2013.176;

Dandona P, Boden WE. Intensive glucose control in hyperglycemic patients with acute coronary syndromes: still smoke, but no fire.... JAMA Intern Med. 2013 Nov 11; 173(20):1905-6. PMID: 24018563; DOI: 10.1001/jamainternmed.2013.8095;

Sedlis SP, Jurkovitz CT, Hartigan PM, Kolm P, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, Boden WE, Weintraub WS. Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial). Am J Cardiol. 2013 Dec 01; 112(11):1703-8. PMID: 24011740; PMCID: PMC5681221; DOI: 10.1016/j.amjcard.2013.07.034;

Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS. Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol. 2013 Nov 12; 62(20):1826-33. PMID: 23973693; PMCID: PMC5661970; DOI: 10.1016/j.jacc.2013.07.051;

Sidhu MS, Boden WE. Optimal medical therapy vs. revascularization on long-term LV function. Eur Heart J. 2013 Nov; 34(43):3339-41. PMID: 23964032; DOI: 10.1093/eurheartj/eht297;

Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013 Aug 17; 382(9892):605-13. PMID: 23953385; DOI: 10.1016/S0140-6736(13)61451-8;

Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.View Related Profiles.

D'Agostino, Ralph
Boden, William

PMID: 24079290

Mancini GB, Hartigan PM, Bates ER, Chaitman BR, Sedlis SP, Maron DJ, Kostuk WJ, Spertus JA, Teo KK, Dada M, Knudtson M, Berman DS, Booth DC, Boden WE, Weintraub WS. Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial. Am Heart J. 2013 Sep; 166(3):481-7. PMID: 24016497; DOI: 10.1016/j.ahj.2013.07.007;

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013 Oct 22; 62(17):1580-4. PMID: 23916935; PMCID: PMC3862446; DOI: 10.1016/j.jacc.2013.07.023;

Acharjee S, Roe MT, Amsterdam EA, Holmes DN, Boden WE. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2013 Oct 15; 112(8):1057-62. PMID: 23891245; DOI: 10.1016/j.amjcard.2013.05.050;

Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93. PMID: 23881958; PMCID: PMC4886540; DOI: 10.1161/STROKEAHA.113.001529;

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation. 2013 Aug 20; 128(8):823-33. PMID: 23852610; DOI: 10.1161/CIRCULATIONAHA.113.002303;

Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):409-18. PMID: 23838107; PMCID: PMC3903667; DOI: 10.1161/CIRCOUTCOMES.113.000139;

Torosoff MT, Sidhu MS, Boden WE. Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease. Lessons from the COURAGE and FAME 2 trials. Herz. 2013 Jun; 38(4):382-6. PMID: 23695652; DOI: 10.1007/s00059-013-3824-0;

Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013 Apr 16; 61(15):1607-15. PMID: 23500281; DOI: 10.1016/j.jacc.2013.01.044;

Maron DJ, Hartigan PM, Neff DR, Weintraub WS, Boden WE. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial). Am J Cardiol. 2013 Jun 01; 111(11):1557-62. PMID: 23538020; DOI: 10.1016/j.amjcard.2013.02.005;

Marzilli M, Merz CN, Boden WE, Bonow RO, Capozza PG, Chilian WM, DeMaria AN, Guarini G, Huqi A, Morrone D, Patel MR, Weintraub WS. Reply: To PMID 22954239. J Am Coll Cardiol. 2013 Jan 22; 61(3):388. PMID: 23328616; DOI: 10.1016/j.jacc.2012.10.021;

Boden WE, Franklin BA, Wenger NK. Physical activity and structured exercise for patients with stable ischemic heart disease. JAMA. 2013 Jan 09; 309(2):143-4. PMID: 23299603; DOI: 10.1001/jama.2012.128367;

Torosoff MT, Fein SA, Boden WE. Does the potential overuse of routine post PCI stress testing and revascularization inspire courage to embrace more evidence-based decision making? Circ Cardiovasc Imaging. 2013 Jan 01; 6(1):2-5. PMID: 23322726; DOI: 10.1161/CIRCIMAGING.112.982165;

Boden WE. COURAGE 5 years on: the message grows stronger. Heart. 2012 Dec; 98(24):1757-60. PMID: 23204531; DOI: 10.1136/heartjnl-2012-302823;

Boden WE, Lansky A, Angiolillo DJ. Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome. Am J Cardiol. 2013 Feb 01; 111(3):439-44. PMID: 23168289; DOI: 10.1016/j.amjcard.2012.10.018;

Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol. 2013 Apr; 29(4):472-82. PMID: 23010084; DOI: 10.1016/j.cjca.2012.07.010;

Marzilli M, Merz CN, Boden WE, Bonow RO, Capozza PG, Chilian WM, DeMaria AN, Guarini G, Huqi A, Morrone D, Patel MR, Weintraub WS. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol. 2012 Sep 11; 60(11):951-6. PMID: 22954239; DOI: 10.1016/j.jacc.2012.02.082;

Boden WE. Which is more enduring--FAME or COURAGE? N Engl J Med. 2012 Sep 13; 367(11):1059-61. PMID: 22924622; DOI: 10.1056/NEJMe1208620;

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012 Oct 04; 367(14):1297-309. PMID: 22920930; DOI: 10.1056/NEJMoa1205512;

Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, Dada M, Mancini GB, Hayes SW, O'Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J. 2012 Aug; 164(2):243-50. PMID: 22877811; DOI: 10.1016/j.ahj.2012.05.018;

O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10; 60(2):106-11. PMID: 22766336; DOI: 10.1016/j.jacc.2012.02.059;

Boden WE, Roberts WC. William Edward Boden, MD: a conversation with the editor. Am J Cardiol. 2012 Jul 01; 110(1):145-59. PMID: 22704294; DOI: 10.1016/j.amjcard.2012.02.035;

Duval S, Massaro JM, Jaff MR, Boden WE, Alberts MJ, Califf RM, Eagle KA, D'Agostino RB, Pedley A, Fonarow GC, Murabito JM, Steg PG, Bhatt DL, Hirsch AT. An evidence-based score to detect prevalent peripheral artery disease (PAD). Vasc Med. 2012 Oct; 17(5):342-51.View Related Profiles.

Murabito, Joanne
Massaro, Joseph
D'Agostino, Ralph
Boden, William

PMID: 22711750; DOI: 10.1177/1358863X12445102;

Boden WE, Finn AV, Patel D, Peacock WF, Thadani U, Zimmerman FH. Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol. 2012 May; 35(5):263-71. PMID: 22528319; PMCID: PMC6652630; DOI: 10.1002/clc.21993;

Gosselin G, Teo KK, Tanguay JF, Gokhale R, Hartigan PM, Maron DJ, Gupta V, Mancini GB, Bates ER, Chaitman BR, Spertus JA, Kostuk WJ, Dada M, Sedlis SP, Berman DS, Shaw LJ, O'Rourke RA, Weintraub WS, Boden WE. Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc analysis of the COURAGE trial). Am J Cardiol. 2012 Apr 01; 109(7):954-9. PMID: 22445578; DOI: 10.1016/j.amjcard.2011.11.023;

Tandar A, Velagapudi KN, Wilson BD, Boden WE. Perioperative antiplatelet management in patients with coronary artery stenting. Hosp Pract (1995). 2012 Apr; 40(2):118-30. PMID: 22615086; DOI: 10.3810/hp.2012.04.977;

Boden WE. Weighing the evidence for decision making about percutaneous coronary intervention in patients with stable coronary artery disease. Circulation. 2012 Apr 17; 125(15):1827-31. PMID: 22441936; DOI: 10.1161/CIRCULATIONAHA.112.100669;

Boden WE. Mounting evidence for lack of PCI benefit in stable ischemic heart disease : what more will it take to turn the tide of treatment?: comment on "initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease". Arch Intern Med. 2012 Feb 27; 172(4):319-21. PMID: 22371920; DOI: 10.1001/archinternmed.2011.2321;

Maron DJ, Stone GW, Berman DS, Mancini GB, Scott TA, Byrne DW, Harrell FE, Shaw LJ, Hachamovitch R, Boden WE, Weintraub WS, Spertus JA. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. Am Heart J. 2011 Dec; 162(6):1034-1043.e13. PMID: 22137077; DOI: 10.1016/j.ahj.2011.09.001;

Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15; 365(24):2255-67. PMID: 22085343; DOI: 10.1056/NEJMoa1107579;

Friedewald VE, Boden WE, Stone GW, Yancy CW, Roberts WC. The editor's roundtable: role of percutaneous coronary intervention and drug-eluting stents in patients with stable coronary heart disease. Am J Cardiol. 2011 Nov 15; 108(10):1417-25. PMID: 22040718; DOI: 10.1016/j.amjcard.2011.06.064;

Mancini GB, Hartigan PM, Bates ER, Sedlis SP, Maron DJ, Spertus JA, Berman DS, Kostuk WJ, Shaw LJ, Weintraub WS, Teo KK, Dada M, Chaitman BR, O'Rourke RA, Boden WE. Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial. Circ Cardiovasc Interv. 2011 Dec 01; 4(6):545-52. PMID: 22045968; DOI: 10.1161/CIRCINTERVENTIONS.110.960062;

Armstrong PW, Boden WE. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann Intern Med. 2011 Sep 20; 155(6):389-91. PMID: 21930857; DOI: 10.7326/0003-4819-155-6-201109200-00008;

Shaw LJ, Mieres JH, Hendel RH, Boden WE, Gulati M, Veledar E, Hachamovitch R, Arrighi JA, Merz CN, Gibbons RJ, Wenger NK, Heller GV. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation. 2011 Sep 13; 124(11):1239-49. PMID: 21844080; DOI: 10.1161/CIRCULATIONAHA.111.029660;

Boden WE. Is myocardial perfusion imaging an important predictor of mortality in women and if so, is this likely cost effective? JACC Cardiovasc Imaging. 2011 Aug; 4(8):889-93. PMID: 21835381; DOI: 10.1016/j.jcmg.2011.07.003;

Mieres JH, Heller GV, Hendel RC, Gulati M, Boden WE, Katten D, Shaw LJ. Signs and symptoms of suspected myocardial ischemia in women: results from the What is the Optimal Method for Ischemia Evaluation in WomeN? Trial. J Womens Health (Larchmt). 2011 Sep; 20(9):1261-8. PMID: 21740192; DOI: 10.1089/jwh.2010.2595;

Maron DJ, Boden WE, Spertus JA, Hartigan PM, Mancini GB, Sedlis SP, Kostuk WJ, Chaitman BR, Shaw LJ, Berman DS, Dada M, Teo KK, Weintraub WS, O'Rourke RA. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2011 Jul 05; 58(2):131-7. PMID: 21718908; DOI: 10.1016/j.jacc.2011.02.046;

Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):172-82. PMID: 21304091; DOI: 10.1161/CIRCOUTCOMES.110.940502;

Maron DJ, Boden WE, Weintraub WS, Calfas KJ, O'Rourke RA. Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use? Curr Treat Options Cardiovasc Med. 2011 Feb; 13(1):16-25. PMID: 21120640

Boden WE, Gupta V, Patel A. Role of a new cardiac catheterization laboratory in advancing cardiovascular care and outcomes in post-myocardial infarction patients. Rev Esp Cardiol. 2011 Feb; 64(2):87-8. PMID: 21272984; DOI: 10.1016/j.recesp.2010.10.012;

Kireyev D, Gupta V, Arkhipov MV, Bhatia A, Paris JA, Boden WE. Approach to the differentiation of wide QRS complex tachycardias. Am Heart Hosp J. 2011; 9(1):E33-6. PMID: 21823074

Fernandez SF, Boden WE. Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials. Curr Atheroscler Rep. 2010 Nov; 12(6):423-31. PMID: 20845088

Brooks MM, Boden WE, Frye RL. Clinical implications of the BARI 2D and COURAGE trials: overview. Coron Artery Dis. 2010 Nov; 21(7):383-5. PMID: 20664331; PMCID: PMC2950885; DOI: 10.1097/MCA.0b013e32833d014a;

Beck H, Boden WE, Patibandla S, Kireyev D, Gutpa V, Campagna F, Cain ME, Marine JE. 50th Anniversary of the first successful permanent pacemaker implantation in the United States: historical review and future directions. Am J Cardiol. 2010 Sep 15; 106(6):810-8. PMID: 21391322

Boden WE. Ranolazine and its anti-ischemic effects: revisiting an old mechanistic paradigm anew? J Am Coll Cardiol. 2010 Sep 14; 56(12):943-5. PMID: 20828646

Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB, Steg PG, Bhatt DL. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25.View Related Profiles.

Massaro, Joseph
D'Agostino, Ralph
Boden, William

PMID: 20802264; DOI: 10.1097/HPC.0b013e3181e7f93e;

Williams DO, Vasaiwala SC, Boden WE. Is optimal medical therapy "optimal therapy" for multivessel coronary artery disease? Optimal management of multivessel coronary artery disease. Circulation. 2010 Sep 07; 122(10):943-5. PMID: 20733095

Chaitman BR, Hartigan PM, Booth DC, Teo KK, Mancini GB, Kostuk WJ, Spertus JA, Maron DJ, Dada M, O'Rourke RA, Weintraub WS, Berman DS, Shaw LJ, Boden WE. Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system? Circ Cardiovasc Qual Outcomes. 2010 Sep; 3(5):476-83. PMID: 20664026

Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE. The in vitro effects of niacin on platelet biomarkers in human volunteers. Thromb Haemost. 2010 Aug; 104(2):311-7. PMID: 20539903

Boden WE, Flather MD, Bhatt DL. Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. Cardiovasc Drugs Ther. 2010 Jun; 24(3):207-16. PMID: 20593231

Fernandez SF, Tandar A, Boden WE. Emerging medical treatment for angina pectoris. Expert Opin Emerg Drugs. 2010 Jun; 15(2):283-98. PMID: 20384546

Sedlis SP, Boden WE. Percutaneous revascularization for stable coronary artery disease: temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv. 2010 May; 3(5):566; author reply 566-7. PMID: 20488418

Kireyev D, Arkhipov MV, Zador ST, Paris JA, Boden WE. Clinical utility of aVR-The neglected electrocardiographic lead. Ann Noninvasive Electrocardiol. 2010 Apr; 15(2):175-80. PMID: 20522059; PMCID: PMC6932457; DOI: 10.1111/j.1542-474X.2010.00359.x;

Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010 Mar 30; 55(13):1348-58. PMID: 20338496

Page BJ, Kireyev D, Boden WE. The role of revascularization versus medical therapy in patients with type 2 diabetes mellitus and coronary artery disease. Curr Diab Rep. 2010 Feb; 10(1):10-5. PMID: 20425061

Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DL. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52. PMID: 20152237

Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, O'Rourke RA, Boden WE, Weintraub WS. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009 Dec 15; 104(12):1647-53. PMID: 19962469

Boden WE, McGovern ME. Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy. Am J Cardiol. 2009 Dec 15; 104(12):1695-6. PMID: 19962477

Barn K, Laftavi M, Pierce D, Ying C, Boden WE, Pankewycz O. Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients. Transpl Int. 2010 Jun; 23(6):574-9. PMID: 20003032

Boden WE, Gupta V. Acute coronary syndromes: selective vs early invasive strategies. Clin Cardiol. 2009 Nov; 32(11):621-6. PMID: 19938050; PMCID: PMC6653383; DOI: 10.1002/clc.20671;

Tandar A, Boden WE. Evolving concepts in selecting optimal strategies for the management of patients with stable coronary disease: pharmacologic or revascularization therapy. Curr Opin Cardiol. 2009 Nov; 24(6):591-5. PMID: 19752728

Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. J Am Coll Cardiol. 2009 Sep 29; 54(14):1303-8. PMID: 19778673

Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11. PMID: 19726929

Maron DJ, Spertus JA, Mancini GB, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2009 Oct 15; 104(8):1055-62. PMID: 19801024

Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol. 2009 Jul 28; 54(5):468-76. PMID: 19628124

Kireyev D, Yun EC, Page BJ, Boden WE. Medical therapy in acute coronary syndromes: which medicines and at what doses? Curr Cardiol Rep. 2009 Jul; 11(4):267-75. PMID: 19563726

Diamond GA, Kaul S, Boden WE. A 300-year-old solution to the health care crisis. Arch Intern Med. 2009 Jun 08; 169(11):1019-21. PMID: 19506168

Boden WE, Taggart DP. Diabetes with coronary disease--a moving target amid evolving therapies? N Engl J Med. 2009 Jun 11; 360(24):2570-2. PMID: 19502646

Mancini GB, Bates ER, Maron DJ, Hartigan P, Dada M, Gosselin G, Kostuk W, Sedlis SP, Shaw LJ, Berman DS, Berger PB, Spertus J, Mavromatis K, Knudtson M, Chaitman BR, O'Rourke RA, Weintraub WS, Teo K, Boden WE. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):320-7. PMID: 20031857

Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2165-75. PMID: 19458363

Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol. 2009 Jul 01; 104(1):1-4. PMID: 19576311

Chaudhry S, Arena R, Wasserman K, Hansen JE, Lewis GD, Myers J, Belardinelli R, LaBudde B, Menasco N, Boden WE. The utility of cardiopulmonary exercise testing in the assessment of suspected microvascular ischemia. Int J Cardiol. 2011 Apr 01; 148(1):e7-9. PMID: 19233492; PMCID: PMC3062706; DOI: 10.1016/j.ijcard.2009.01.055;

Sedlis SP, Boden WE, Weintraub WS, Maron DS, O'Rourke RA, Berman DS, Mancini GB. Re: One year perspective on COURAGE. Catheter Cardiovasc Interv. 2009 Feb 15; 73(3):428. PMID: 19133682

Chaudhry S, Arena R, Wasserman K, Hansen JE, Lewis GD, Myers J, Chronos N, Boden WE. Exercise-induced myocardial ischemia detected by cardiopulmonary exercise testing. Am J Cardiol. 2009 Mar 01; 103(5):615-9. PMID: 19231322; PMCID: PMC3035935; DOI: 10.1016/j.amjcard.2008.10.034;

Boden WE. Interpreting the results of the COURAGE trial: a non-interventionalist perspective. Rev Cardiovasc Med. 2009; 10 Suppl 2:S34-44. PMID: 19898280

Boden WE, Gupta V. Reperfusion strategies in acute ST-segment elevation myocardial infarction. Curr Opin Cardiol. 2008 Nov; 23(6):613-9. PMID: 18830078

Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation. 2008 Nov 11; 118(20):2038-46. PMID: 18955665

Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008 Sep; 1(1):12-20. PMID: 20031783

Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE, Ohman EM, Smith SC, Peterson ED. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2008 Oct; 29(20):2480-8. PMID: 18716006

Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE, Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008 Aug 14; 359(7):677-87. PMID: 18703470

O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 02; 300(1):71-80. PMID: 18594042

Eid F, Boden WE. The evolving role of medical therapy for chronic stable angina. Curr Cardiol Rep. 2008 Jul; 10(4):263-71. PMID: 18611360

Boden WE. Management of chronic coronary disease: is the pendulum returning to equipoise? Am J Cardiol. 2008 May 22; 101(10A):69D-74D. PMID: 18474277

Boden WE, Diamond GA. DTCA for PTCA--crossing the line in consumer health education? N Engl J Med. 2008 May 22; 358(21):2197-200. PMID: 18480195

Mamkin I, Vaksman M, Kiernan FJ, McKay RG, Boden WE. Letter by Mamkin et al regarding article, "weekend onset of acute myocardial infarction does not have a negative impact on outcome in Japan". Circ J. 2008 May; 72(5):864; author reply 865. PMID: 18441476

Roe MT, Chen AY, Delong ER, Boden WE, Calvin JE, Cairns CB, Smith SC, Pollack CV, Brindis RG, Califf RM, Gibler WB, Ohman EM, Peterson ED. Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. Am Heart J. 2008 Jul; 156(1):185-92. PMID: 18585515

Boden WE, Maron DJ. Reducing post-myocardial infarction mortality in the elderly: the power and promise of secondary prevention. J Am Coll Cardiol. 2008 Apr 01; 51(13):1255-7. PMID: 18371554

Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, Ohman EM, Roe MT, Boden WE, Harrington RA, Peterson ED. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Jun; 155(6):1047-53. PMID: 18513518

Taggart DP, Kaul S, Boden WE, Ferguson TB, Guyton RA, Mack MJ, Sergeant PT, Shemin RJ, Smith PK, Yusuf S. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol. 2008 Mar 04; 51(9):885-92. PMID: 18308155

Boden WE, Shah PK, Gupta V, Ohman EM. Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. Prog Cardiovasc Dis. 2008 Mar-Apr; 50(5):311-51. PMID: 18313479

Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11; 117(10):1283-91. PMID: 18268144

Boden WE, Hoekstra J, Miller CD. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. Am J Emerg Med. 2008 Feb; 26(2):212-20. PMID: 18272105

Boden WE, O'Rourke RA, Teo KK, Weintraub WS. The corrected values for duration and frequency of angina at baseline in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial. Am J Cardiol. 2007 Nov 15; 100(10):1604. PMID: 18051252

Boden WE. Interpreting the COURAGE trial. It takes COURAGE to alter our belief system. Cleve Clin J Med. 2007 Sep; 74(9):623-5, 629-33. PMID: 17879516

Boden WE, Eagle K, Granger CB. Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol. 2007 Sep 04; 50(10):917-29. PMID: 17765117

Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007 Sep; 28(18):2200-7. PMID: 17673448

Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 May 15; 49(19):1982-8. PMID: 17498584

Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12; 356(15):1503-16. PMID: 17387127

Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Gau G, Weintraub WS. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Am J Cardiol. 2007 Jan 15; 99(2):208-12. PMID: 17223420

Deaton C, Kimble LP, Veledar E, Hartigan P, Boden WE, O'Rourke RA, Weintraub WS. The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status. Heart Lung. 2006 Sep-Oct; 35(5):315-23. PMID: 16963363

Shaw LJ, Heller GV, Casperson P, Miranda-Peats R, Slomka P, Friedman J, Hayes SW, Schwartz R, Weintraub WS, Maron DJ, Dada M, King S, Teo K, Hartigan P, Boden WE, O'Rourke RA, Berman DS. Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424. J Nucl Cardiol. 2006 Sep; 13(5):685-98. PMID: 16945749

Favarato ME, Hueb W, Boden WE, Lopes N, Nogueira CR, Takiuti M, Góis AF, Borges JC, Favarato D, Aldrighi JM, Oliveira SA, Ramires JA. Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. Int J Cardiol. 2007 Apr 04; 116(3):364-70. PMID: 16876891

Diercks DB, Roe MT, Mulgund J, Pollack CV, Kirk JD, Gibler WB, Ohman EM, Smith SC, Boden WE, Peterson ED. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. Am Heart J. 2006 Jul; 152(1):140-8. PMID: 16824844

Coleman CI, McKay RG, Boden WE, Mather JF, White CM. Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals. Clin Ther. 2006 Jul; 28(7):1054-62. PMID: 16990084

Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006 Jun; 151(6):1173-9. PMID: 16781214

Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J. 2006 Jun; 151(6):1180-5. PMID: 16781215

Rogers IS, Rinaldi MJ, Humphrey CB, Boden WE, Dougherty JE. Postpartum dissection of the left main coronary artery. Clin Cardiol. 2006 Apr; 29(4):175-8. PMID: 16649728; PMCID: PMC6654591; DOI: 10.1002/clc.4960290410;

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20; 354(16):1706-17. PMID: 16531616

Boden WE. What is the optimum role and timing of early invasive management of patients with acute coronary syndromes? Nat Clin Pract Cardiovasc Med. 2006 Feb; 3(2):72-3. PMID: 16446772

Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV, Foody JM, Boden WE, Smith SC, Gibler WB, Ohman EM, Peterson ED. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005 Oct 18; 46(8):1479-87. PMID: 16226171

Boden WE. Acute coronary syndromes without ST-segment elevation--what is the role of early intervention? N Engl J Med. 2005 Sep 15; 353(11):1159-61. PMID: 16162887

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2005 Sep; 150(3):401. PMID: 16169314

Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005 Jun 15; 293(23):2908-17. PMID: 15956636

Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol. 2005 Mar 15; 45(6):832-7. PMID: 15766815

Kalus JS, Caron MF, White CM, Mather JF, Gallagher R, Boden WE, Kluger J. Impact of fluid balance on incidence of atrial fibrillation after cardiothoracic surgery. Am J Cardiol. 2004 Dec 01; 94(11):1423-5. PMID: 15566917

Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC, Pollack CV, Gibler WB, Ohman EM. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 03; 292(17):2096-104. PMID: 15523070

Elkoustaf RA, Boden WE. Is there a gender paradox in the early invasive strategy for non ST-segment elevation acute coronary syndromes? Eur Heart J. 2004 Sep; 25(18):1559-61. PMID: 15351153

Danias PG, Papaioannou GI, Ahlberg AW, O'Sullivan DM, Mann A, Boden WE, Heller GV. Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy. Am J Cardiol. 2004 Jul 01; 94(1):14-9. PMID: 15219501

Boden WE. Surgery, angioplasty, or medical therapy for symptomatic multivessel coronary artery disease: is there an indisputable "winning strategy" from evidence-based clinical trials? J Am Coll Cardiol. 2004 May 19; 43(10):1752-4. PMID: 15145094

Boden WE, Phinney AO, Low HB, Kluger J, McLean C, Shapiro R, Hammond J, Kiernan FJ, Humphrey C, Rossi MA, Fieldman A, McKay RG, Gillam LD, Clyne CA, Heller GV, Thompson PD. The origins and development of the Cardiovascular Program at Hartford Hospital. 150th Anniversary of Hartford Hospital. Conn Med. 2004 May; 68(5):259-68. PMID: 15171261

Turcot DB, Kiernan FJ, McKay RG, Grey NJ, Boden W, Perdrizet GA. Acute hyperglycemia: implications for contrast-induced nephropathy during cardiac catheterization. Diabetes Care. 2004 Feb; 27(2):620-1. PMID: 14747256

Boden WE. Practical approach to incorporating new studies and guidelines for antiplatelet therapy in the management of patients with non-ST-segment elevation acute coronary syndrome. Am J Cardiol. 2004 Jan 01; 93(1):69-72. PMID: 14697469

Januzzi JL, Cannon CP, Theroux P, Boden WE. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Am Heart J. 2003 Nov; 146(5):764-74. PMID: 14597924

Boden WE. Interpretation of new treatment guidelines for non-ST-segment elevation acute coronary syndromes: "ischemia-guided" versus "early invasive" strategies. Minerva Cardioangiol. 2003 Oct; 51(5):447-61. PMID: 14551515

Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol. 2003 Jul; 18(4):278-85. PMID: 12858126

Silverman IE, Kiernan FJ, Kelsey AM, Brakoniecki JJ, Kazi FA, Dougherty JE, Boden WE, McKay RG. Initial experience with a transcatheter septal closure system for secondary stroke prevention in patients with interatrial septal defects. Conn Med. 2003 Mar; 67(3):135-44. PMID: 12687787

Boden WE, Pepine CJ. Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention. J Am Coll Cardiol. 2003 Feb 19; 41(4 Suppl S):1S-6S. PMID: 12644334

Boden WE. "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. J Am Coll Cardiol. 2003 Feb 19; 41(4 Suppl S):113S-122S. PMID: 12644349

Yarlagadda RK, Boden WE. Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: are we all becoming "interventional" cardiologists? J Am Coll Cardiol. 2002 Dec 04; 40(11):1915-8. PMID: 12475449

Samaha FF, Kimmel SE, Kizer JR, Goyal A, Wade M, Boden WE. Usefulness of the TIMI risk score in predicting both short- and long-term outcomes in the Veterans Affairs Non-Q-Wave Myocardial Infarction Strategies In-Hospital (VANQWISH) Trial. Am J Cardiol. 2002 Nov 01; 90(9):922-6. PMID: 12398955

Boden WE. Is it time to reassess the optimal timing of coronary artery bypass graft surgery following acute myocardial infarction? Am J Cardiol. 2002 Jul 01; 90(1):35-8. PMID: 12088776

Boden WE. The role of pharmacotherapy and catheter-based intervention in the management of patients with non-ST-segment elevation acute coronary syndromes. Curr Cardiol Rep. 2002 Jul; 4(4):260-71. PMID: 12052265

Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. Am J Cardiol. 2002 Jun 01; 89(11):1300-2. PMID: 12031733

Goyal A, Samaha FF, Boden WE, Wade MJ, Kimmel SE. Stress test criteria used in the conservative arm of the FRISC-II trial underdetects surgical coronary artery disease when applied to patients in the VANQWISH trial. J Am Coll Cardiol. 2002 May 15; 39(10):1601-7. PMID: 12020486

Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP, Selker HP, Steele P, Zalenski RJ. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J. 2002 May; 143(5):777-89. PMID: 12040337

Danias PG, Ahlberg AW, Travin MI, Mahr NC, Abreu JE, Marini D, Mann A, Mather JF, Boden WE, Heller GV. Visual assessment of left ventricular perfusion and function with electrocardiography-gated SPECT has high intraobserver and interobserver reproducibility among experienced nuclear cardiologists and cardiology trainees. J Nucl Cardiol. 2002 May-Jun; 9(3):263-70. PMID: 12032474

Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002 May 01; 39(9):1456-63. PMID: 11985907

Barnett PG, Chen S, Boden WE, Chow B, Every NR, Lavori PW, Hlatky MA. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: results of a randomized trial. Circulation. 2002 Feb 12; 105(6):680-4. PMID: 11839621

McKay RG, Boden WE. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Cardiol. 2001 Nov; 16(6):364-9. PMID: 11704707

Boden WE. Defining the optimal pharmacotherapy of non-ST-segment elevation (NSTE) acute coronary syndromes (ACS): a rapidly moving target. Curr Opin Cardiol. 2001 Nov; 16(6):370-4. PMID: 11704708

Popma JJ, Hunninghake DB, Arad Y, Blumenthal RS, Boden WE, Selwyn AP. Roundtable discussion: therapeutic challenges and deficiencies. Am J Cardiol. 2001 Oct 18; 88(8A):42K-43K. PMID: 11694219

Boden WE. Interpreting new treatment guidelines for non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2001 Oct 18; 88(8A):19K-24K. PMID: 11694215

Boden WE, McKay RG, Cabin HS, Radford MJ, Krumholz HM, Zaret BL, Garner L, Bull MB, Fisherkeller M, Kosinski EJ, Krauthamer MJ, Maljanian R, McDowell AV, Sands MJ, Schwartz KV, Seltzer JP, Hager JD. The Connecticut Cardiovascular Consortium: a unique, state-wide research collaboration to advance clinical outcomes in patients with heart disease. Conn Med. 2001 Oct; 65(10):597-604. PMID: 11702518

McKay RG, Mennett RA, Gallagher RC, Horowitz L, Takata H, Low HB, Hammond JA, Underhill DJ, Preissler PL, Humphrey CB, Ellison LH, Boden WE. A comparison of ON-PUMP vs OFF-PUMP coronary artery bypass surgery among low, intermediate, and high-risk patients: the Hartford Hospital experience. Conn Med. 2001 Sep; 65(9):515-21. PMID: 11678056

Boden WE, McKay RG. Optimal treatment of acute coronary syndromes--an evolving strategy. N Engl J Med. 2001 Jun 21; 344(25):1939-42. PMID: 11419433

Fram DB, Giri S, Jamil G, Mitchel JF, Boden WE, Din S, Kiernan FJ. Suture closure of the femoral arteriotomy following invasive cardiac procedures: a detailed analysis of efficacy, complications, and the impact of early ambulation in 1,200 consecutive, unselected cases. Catheter Cardiovasc Interv. 2001 Jun; 53(2):163-73. PMID: 11387599

Messerli FH, Hansen JF, Gibson RS, Schechtman KB, Boden WE. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens. 2001 May; 19(5):977-82. PMID: 11393682

Boden WE, Vray M, Eschwege E, Lauret D, Scheldewaert R. Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem. Clin Cardiol. 2001 Jan; 24(1):73-9. PMID: 11195610

Wexler LF, Blaustein AS, Lavori PW, Lehmann KG, Wade M, Boden WE. Non-Q-wave myocardial infarction following thrombolytic therapy: a comparison of outcomes in patients randomized to invasive or conservative post-infarct assessment strategies in the Veterans Affairs non-Q-wave Infarction Strategies In-Hospital (VANQWISH) Trial. J Am Coll Cardiol. 2001 Jan; 37(1):19-25. PMID: 11153737

Boden WE. Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2000 Dec 28; 86(12B):42M-47M. PMID: 11206018

Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol. 2000 Dec 21; 86(12A):19L-22L. PMID: 11374850

Pearson TA, Boden WE. The imperative to raise low levels of high-density lipoprotein in cholesterol--a better clinical strategy in the prevention and treatment of coronary artery disease. Introduction. Am J Cardiol. 2000 Dec 21; 86(12A):1L-4L. PMID: 11374851

Heggunje PS, Wade MJ, O'Rourke RA, Kleiger RE, Deedwania PC, Lavori PW, Boden WE. Early invasive versus ischaemia-guided strategies in the management of non-Q wave myocardial infarction patients with and without prior myocardial infarction; results of Veterans Affairs Non-Q Wave Infarction Strategies in Hospital (VANQWISH) trial. Eur Heart J. 2000 Dec; 21(24):2014-25. PMID: 11102252

Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies. Am J Cardiol. 2000 Aug 01; 86(3):275-9. PMID: 10922432

Boden WE, van Gilst WH, Scheldewaert RG, Starkey IR, Carlier MF, Julian DG, Whitehead A, Bertrand ME, Col JJ, Pedersen OL, Lie KI, Santoni JP, Fox KM. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) Lancet. 2000 May 20; 355(9217):1751-6. PMID: 10832825

Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol. 2000 Mar 01; 85(5):645-50, A10. PMID: 11078282

Ferraro P, Khawari A, Boden WE. Dofetilide for atrial fibrillation. N Engl J Med. 2000 Jan 27; 342(4):289; author reply 290. PMID: 10660386

Stratmann HG, Kleiger RE, Ferry DR, Zoble RG, Chow BK, Lavori PW, Boden WE. Comparison based on age of baseline electrocardiographic abnormalities in non-Q-wave myocardial infarction. VANQWISH Trial Research Investigators. Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital. J Am Geriatr Soc. 1999 Jul; 47(7):870-2. PMID: 10404934

Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Kleiger RE, Pepine CJ, Ferry DR, Chow BK, Lavori PW. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998 Jun 18; 338(25):1785-92. PMID: 9632444

Boden W. Deferred invasive treatment was associated with fewer MIs in patients with inducible ischemia post-AMI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):14-5. PMID: 16379779

Boden W. PTCA in comparison to medical therapy was associated with a significant excess of death and non-fatal MI among patients with angina. Evid Based Cardiovasc Med. 1998 Mar; 2(1):14-5. PMID: 16379778

Ferry DR, O'Rourke RA, Blaustein AS, Crawford MH, Deedwania PC, Carson PE, Pepine CJ, Thomas RG, Hlatky MA, Leppo JA, Iwane MK, Kleiger RE, Zoble RG, Dai H, Chow BK, Lavori PW, Boden WE. Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research Investigators. J Am Coll Cardiol. 1998 Feb; 31(2):312-20. PMID: 9462573

Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997 Aug 05; 96(3):856-63. PMID: 9264493

Gibson RS, Boden WE. Calcium channel antagonists: friend or foe in postinfarction patients? Am J Hypertens. 1996 Dec; 9(12 Pt 2):172S-176S. PMID: 8968429

Boden WE, Ziesche S, Carson PE, Conrad CH, Syat D, Cohn JN. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. Am J Cardiol. 1996 May 15; 77(12):1078-82.View Related Profiles.

Conrad, Chester
Boden, William

PMID: 8644661

Boden WE. Anti-ischaemic therapy during the follow-up phase of acute coronary syndromes. Is there a role for calcium channel blockers? Drugs. 1996; 52 Suppl 4:20-30. PMID: 8913715

Boden WE, Brooks WW, Conrad CH, Bing OH, Hood WB. Incomplete, delayed functional recovery late after reperfusion following acute myocardial infarction: "maimed myocardium". Am Heart J. 1995 Oct; 130(4):922-32. PMID: 7572610

Boden WE, Scheldewaert R, Walters EG, Whitehead A, Coltart DJ, Santoni JP, Belgrave G, Starkey IR. Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) Research Group. Am J Cardiol. 1995 Jun 01; 75(16):1120-3. PMID: 7762497

Jaffe ND, Boden WE. Spontaneous transient, inverted U waves as initial electrocardiographic manifestation of unstable angina. Am Heart J. 1995 May; 129(5):1028-30. PMID: 7732962

Szyniszewski AM, Carson PE, Sakwa M, Lundstrom T, Boden WE. Valve replacement for tricuspid regurgitation appearing late after healing of left ventricular posterior wall and right ventricular acute myocardial infarction. Am J Cardiol. 1994 Mar 15; 73(8):616-7. PMID: 8147314

Boden WE, Moss AJ, Herbert PN, Saritelli A, Oakes D, Eberly S. Effect of long-term diltiazem administration on serum lipids in post-myocardial infarction survivors. Multicenter Diltiazem Post-Infarction Trial Research Group. Am J Cardiol. 1994 Mar 01; 73(7):513-4. PMID: 8141095

Krone RJ, Greenberg H, Dwyer EM, Kleiger RE, Boden WE. Long-term prognostic significance of ST segment depression during acute myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. J Am Coll Cardiol. 1993 Aug; 22(2):361-7. PMID: 8335805

Rubins HB, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993 Jan 1; 71(1):45-52.View Related Profiles.

Robins, Sander
Boden, William

PMID: 8420235

Jaffe AS, Deedwania PC, Higginson LA, Boden WE, Mehta JL, Ferlinz J, Walsh RA, Sullivan JM, Vokonas PS, Cabin H, et al. Diagnostic and therapeutic implications: exploration through case discussions. Am J Cardiol. 1992 Nov 16; 70(16):45F-48F.View Related Profiles.

Vokonas, Pantel
Boden, William

PMID: 1442602

Deedwania PC, Schroeder JS, Boden WE. The Council for Myocardial Ischemia and Infarction: advisory group reports on silent myocardial ischemia, heart rate control, and post-myocardial infarction management. Am J Cardiol. 1992 Nov 16; 70(16):39F-44F. PMID: 1442601

Boden WE. The post-myocardial infarction patient with hypertension. Long-term outcome. Postgrad Med. 1992 Sep 01; 92(3):173-5, 179-80. PMID: 1355600

Boden WE. Non-Q-wave myocardial infarction: a prognostic paradox. Hosp Pract (Off Ed). 1992 Jul 15; 27(7):129-33, 137-8, 140 passim. PMID: 1629258

Boden WE, Moss AJ, Oakes D. Hypolipidemic effect of type Ia antiarrhythmic agents in postinfarction patients. Circulation. 1992 Jun; 85(6):2039-44. PMID: 1591822

Schechtman KB, Kleiger RE, Boden WE, Capone RJ, Schwartz DJ, Roberts R, Gibson RS. The relationship between 1-year mortality and infarct location in patients with non-Q wave myocardial infarction. Am Heart J. 1992 May; 123(5):1175-81. PMID: 1575129

Pepine CJ, Kern MJ, Boden WE. Advisory group reports on silent myocardial ischemia, acute intervention after myocardial infarction, and postinfarction management. Am J Cardiol. 1992 Mar 06; 69(7):41B-46B. PMID: 1543142

Boden WE. Meta-analysis in clinical trials reporting: has a tool become a weapon? Am J Cardiol. 1992 Mar 01; 69(6):681-6. PMID: 1536118

Wallis DE, Boden WE, Califf R, Crawford MH, Hakki AH, Iskandrian AS, Labovitz A, O'Connor C, Sutton R, Scanlon PJ. Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. Am Heart J. 1991 Oct; 122(4 Pt 1):949-54. PMID: 1681722

Boden WE. Electrocardiographic correlates of reperfusion status after thrombolysis: is the "incomplete" or "interrupted" infarction a non-Q-wave infarction? Am J Cardiol. 1991 Aug 15; 68(5):520-4. PMID: 1872281

Boden WE, Krone RJ, Kleiger RE, Oakes D, Greenberg H, Dwyer EJ, Miller JP, Abrams J, Coromilas J, Goldstein R, et al. Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction. The Multicenter Diltiazem Post-Infarction Trial Research Group. Am J Cardiol. 1991 Feb 15; 67(5):335-42. PMID: 1994656

Boden WE. Calcium-channel blockers as adjuvant therapy postthrombolysis. J Cardiovasc Pharmacol. 1991; 18 Suppl 10:S102-6. PMID: 1724997

Boden WE. New concepts for the treatment of unstable angina: role for intravenous diltiazem. J Cardiovasc Pharmacol. 1991; 18 Suppl 9:S1-6. PMID: 1725535

Schechtman KB, Capone RJ, Kleiger RE, Gibson RS, Schwartz DJ, Roberts R, Boden WE. Differential risk patterns associated with 3 month as compared with 3 to 12 month mortality and reinfarction after non-Q wave myocardial infarction. The Diltiazem Reinfarction Study Group. J Am Coll Cardiol. 1990 Apr; 15(5):940-7. PMID: 2179363

Vybiral T, Bryg RJ, Maddens ME, Bhasin SS, Cronin S, Boden WE, Lehmann MH. Effects of transdermal scopolamine on heart rate variability in normal subjects. Am J Cardiol. 1990 Mar 01; 65(9):604-8. PMID: 2309630

Kleiman NS, Schechtman KB, Young PM, Goodman DA, Boden WE, Pratt CM, Roberts R. Lack of diurnal variation in the onset of non-Q wave infarction. Circulation. 1990 Feb; 81(2):548-55. PMID: 1967558

Kleiger RE, Boden WE, Schechtman KB, Gibson RS, Schwartz DJ, Geiger BJ, Capone RJ, Roberts R. Frequency and significance of late evolution of Q waves in patients with initial non-Q-wave acute myocardial infarction. Diltiazem Reinfarction Study Group. Am J Cardiol. 1990 Jan 01; 65(1):23-7. PMID: 2403730

Boden WE. Management of non-Q-wave myocardial infarction: role of diltiazem versus beta-blocker therapy. J Cardiovasc Pharmacol. 1990; 16 Suppl 6:S55-60. PMID: 1707117

Schechtman KB, Capone RJ, Kleiger RE, Gibson RS, Schwartz DJ, Roberts R, Young PM, Boden WE. Risk stratification of patients with non-Q wave myocardial infarction. The critical role of ST segment depression. The Diltiazem Reinfarction Study Research Group. Circulation. 1989 Nov; 80(5):1148-58. PMID: 2805257

Boden WE, Gibson RS, Kleiger RE, Schechtman KB, Capone RJ, Schwartz DJ, Roberts R. Importance of early recurrent ischemia on one-year survival after non-Q-wave acute myocardial infarction. Diltiazem Reinfarction Study Research Group. Am J Cardiol. 1989 Oct 01; 64(12):799-801. PMID: 2801533

Boden WE. Strategies for managing the patient with acute non-Q-wave myocardial infarction. Clin Cardiol. 1989 Jul; 12(7 Suppl 3):III33-40. PMID: 2575020

Vybiral T, Bryg RJ, Maddens ME, Boden WE. Effect of passive tilt on sympathetic and parasympathetic components of heart rate variability in normal subjects. Am J Cardiol. 1989 May 01; 63(15):1117-20. PMID: 2705383

Boden WE, Kleiger RE, Gibson RS, Reddy BR, Schechtman KB, Schwartz DJ, Capone RJ, Roberts R. Favourable long term prognosis in patients with non-Q wave acute myocardial infarction not associated with specific electrocardiographic changes. Diltiazem Reinfarction Study Research Group. Br Heart J. 1989 May; 61(5):396-402. PMID: 2660893; PMCID: PMC1216690

Boden WE, Gibson RS, Schechtman KB, Kleiger RE, Schwartz DJ, Capone RJ, Roberts R. ST segment shifts are poor predictors of subsequent Q wave evolution in acute myocardial infarction. A natural history study of early non-Q wave infarction. Circulation. 1989 Mar; 79(3):537-48. PMID: 2645062

Boden WE, Spodick DH. Diagnostic significance of precordial ST-segment depression. Am J Cardiol. 1989 Feb 01; 63(5):358-61. PMID: 2643846

Boden WE, Kleiger RE, Schechtman KB, Capone RJ, Schwartz DJ, Gibson RS. Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction. Am J Cardiol. 1988 Nov 15; 62(16):1000-4. PMID: 2973215

Stone PH, Ware JH, DeWood MA, Gore JM, Eich RH, Pietro DA, Parisi AF, Nesto RW, Boden WE, Sharma SC, et al. The efficacy of the addition of nifedipine in patients with mixed angina compared to patients with classic exertional angina: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 1988 Oct; 116(4):961-71.View Related Profiles.

Pietro, Daniel
Boden, William

PMID: 2902779

Mamby SA, Bradley AB, Boden WE. Early precordial ST-segment depression due to isolated acute right or left circumflex coronary artery occlusion. Am J Cardiol. 1987 Sep 15; 60(8):726-8. PMID: 3661444

Gibson RS, Young PM, Boden WE, Schechtman K, Roberts R. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study. Am J Cardiol. 1987 Aug 01; 60(4):203-9. PMID: 3303886

Bough EW, Johnson EE, Zacks SI, Boden WE, Mandel A, Medeiros AA, Korr KS, Shulman RS, Yashar JJ. Echocardiographic diagnosis of an infected myxoma in an atypical location. Am Heart J. 1987 Apr; 113(4):1031-2. PMID: 3565231

Boden WE, Kleiger RE, Gibson RS, Schwartz DJ, Schechtman KB, Capone RJ, Roberts R. Electrocardiographic evolution of posterior acute myocardial infarction: importance of early precordial ST-segment depression. Am J Cardiol. 1987 Apr 01; 59(8):782-7. PMID: 3825938

Kohl DW, Bough EW, Korr KS, Boden WE, Gandsman EJ. Asymmetric distribution of left ventricular asynergy in coronary artery disease and its relation to coronary stenoses. Am J Cardiol. 1987 Mar 01; 59(6):543-6. PMID: 3825892

Nevin MF, Korr KS, Bough EW, Felix JM, Shulman RS, Boden WE. Consecutive ST segment depression and elevation in the same electrocardiographic leads during an asymptomatic exercise treadmill test. Am Heart J. 1987 Mar; 113(3):822-5. PMID: 3825873

Pratt CM, Gibson R, Boden W, Theroux P, Strauss H, Gheorghiade M, Capone R, Crawford M, Schlant R, Arensberg D, et al. Design of a multicenter, double-blind study to assess the effects of prophylactic diltiazem on early reinfarction after non-Q-wave acute myocardial infarction: diltiazem reinfarction study. Am J Cardiol. 1986 Nov 01; 58(10):906-10. PMID: 3535473

Boden WE, More G, Sharma S, Bough EW, Korr KS, Young PM, Shulman RS. No increase in serum digoxin concentration with high-dose diltiazem. Am J Med. 1986 Sep; 81(3):425-8. PMID: 3752143

Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986 Aug 14; 315(7):423-9. PMID: 3526151

Boden WE, Bough EW, Reichman MJ, Rich VB, Young PM, Korr KS, Shulman RS. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation. 1985 Jun; 71(6):1197-205. PMID: 2859931

Boden WE, Sadaniantz A. Ventricular septal rupture during ibuprofen therapy for pericarditis after acute myocardial infarction. Am J Cardiol. 1985 Jun 01; 55(13 Pt 1):1631-2. PMID: 4003309

Boden WE, Korr KS, Bough EW. Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris. JAMA. 1985 Feb 22; 253(8):1131-5. PMID: 2857206

Boden WE, Bough EW, Korr KS, Russo J, Gandsman EJ, Shulman RS. Inferoseptal myocardial infarction: another cause of precordial ST-segment depression in transmural inferior wall myocardial infarction? Am J Cardiol. 1984 Dec 01; 54(10):1216-23. PMID: 6507293

Bough EW, Boden WE, Korr KS, Gandsman EJ. Left ventricular asynergy in electrocardiographic "posterior" myocardial infarction. J Am Coll Cardiol. 1984 Aug; 4(2):209-15. PMID: 6736462

Bough EW, Boden WE, Gandsman EJ, Benham ID, McEnany MT, Shulman RS. Radionuclide diagnosis of left atrial myxoma with computer-generated functional images. Am J Cardiol. 1983 Dec 01; 52(10):1365-7. PMID: 6606354

Boden WE, Funk EJ, Carleton RA, Benham I, Khan AH, Lasser A, McEnany MT. Left ventricular hemangioma masquerading as Mycoplasma pericarditis. Am Heart J. 1983 Oct; 106(4 Pt 1):771-4. PMID: 6225326

Boden WE, Bough EW, Benham I, Shulman RS. Unstable angina with episodic ST segment elevation and minimal creatine kinase release culminating in extensive, recurrent infarction. J Am Coll Cardiol. 1983 Jul; 2(1):11-20. PMID: 6602159

Boden WE, Fisher A, Medeiros A, Benham I, McEnany MT. Bioprosthetic endocarditis due to Cryptococcus neoformans. J Cardiovasc Surg (Torino). 1983 Mar-Apr; 24(2):164-6. PMID: 6841440

Boden WE. Anaphylactoid pulmonary edema ("shock lung") and hypotension after radiologic contrast media injection. Chest. 1982 Jun; 81(6):759-61. PMID: 7075314

Boden WE, Bough EW, Korr KS, Benham I, Gheorghiade M, Caputi A, Shulman RS. Exercise-induced coronary spasm with S-T segment depression and normal coronary arteriography. Am J Cardiol. 1981 Jul; 48(1):193-7. PMID: 7246443

Sherman LG, Liang C, Boden WE, Hood WB. The effect of verapamil on mechanical performance of acutely ischemic and reperfused myocardium in the conscious dog. Circ Res. 1981 Feb; 48(2):224-32.View Related Profiles.

Liang, Chang-seng
Boden, William

PMID: 7460198

Boden WE, Bough EW, Benham ID, Shulman RS. The coronary care concept: a review of past achievements and a glance toward the next decade. R I Med J. 1981 Feb; 64(2):104-12. PMID: 6784229

Boden WE, Liang C, Hood WB. Postextrasystolic potentiation of regional mechanical performance during prolonged myocardial ischemia in the dog. Circulation. 1980 Jun; 61(6):1063-70.View Related Profiles.

Liang, Chang-seng
Boden, William

PMID: 7371119

Boden WE, Liang CS, Apstein CS, Hood WB. Experimental myocardial infarction. XVI. The detection of inotropic contractile reserve with postextrasystolic potentiation in acutely ischemic canine myocardium. Am J Cardiol. 1978 Mar; 41(3):523-30.View Related Profiles.

Liang, Chang-seng
Boden, William

PMID: 75688

Boden WE, Smulyan H, Potts J, Johnson LW, Obeid AI, Eich RH. Elevated ejection fractions in patients with the anginal syndrome and normal coronary arteriograms. Cathet Cardiovasc Diagn. 1978; 4(3):249-63. PMID: 737729

Boden WE. Letter: Prognosis in myocardial infarction. Ann Intern Med. 1975 Jul; 83(1):119-20. PMID: 1147426

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 392 publications over 45 distinct years, with a maximum of 22 publications in 2020 and 2022

Bar chart showing 392 publications over 45 distinct years, with a maximum of 22 publications in 2020 and 2022

Year	Publications
1980	1
1981	3
1982	1
1983	4
1984	2
1985	3
1986	3
1987	6
1988	2
1989	7
1990	5
1991	5
1992	8
1993	2
1994	2
1995	3
1996	3
1997	1
1998	4
1999	1
2000	8
2001	11
2002	10
2003	6
2004	8
2005	5
2006	11
2007	6
2008	17
2009	19
2010	15
2011	13
2012	15
2013	20
2014	10
2015	14
2016	15
2017	9
2018	16
2019	13
2020	22
2021	19
2022	22
2023	18
2024	4

Media Mentions

Recent (within 3 months)

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

STAT 2/19/2024

Older

Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups

TCTMD 5/9/2023

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

TCTMD 1/25/2022

'Profound' Benefit Found for Staying on Meds Long After Coronary Revascularization

Medpage Today 6/28/2021

Contentious ISCHEMIA Deep Dive: Extent of Revascularization Key?

Medscape 5/27/2021

Meta-analysis Muses Over ISCHEMIA Message Had Trial Lasted Longer

Medscape 5/19/2021

Stable CAD With High-Risk Anatomy Warrants PCI or CABG, APPROACH Suggests

TCTMD 1/5/2021

Economic value of alirocumab good if LDL greater than 100 mg/dL

Healio 6/26/2020

A Conversation With William E. Boden, MD, FACC, FAHA

Healio 1/25/2019

Some reasons not to rush into open-heart surgery

The Huffington Post 2/23/2018

2012-2015 Greater Albany Capital Region/Hudson Valley, NY: Selected as one of the “Best Doctors in Cardiovascular Medicine"

2008 D’Youville College, Buffalo, NY: Thirteenth Annual Award for Achievement in Health Care

2002-2004 Connecticut Magazine and Hartford Magazine: Selected as one of the top Cardiology physicians in Connecticut

2001-2015 Selected for inclusion in “Best Doctors in America” (15 consecutive years)

2001-2002 Hartford Hospital: Outstanding Teacher of the Year in Cardiology

1994 Boston University Medical Center/VAMC: Medical House Staff Award for Outstanding Clinical Teacher of the Year

1992 Boston University Medical Center/VAMC: Medical House Staff Award for Outstanding Clinical Teacher of the Year

1985 Miriam Hospital: Medical House Staff Award for Outstanding Clinical Teaching

1984-1986 Rhode Island Department of Health: Principal Consultant, Cardiovascular Diseases

1983 American Heart Association: Cardiovascular Research Grant-in-Aid

1978 American College of Cardiology: Young Investigators' Award Finalist

1977 American Heart Association: Cardiovascular Research Grant-in-Aid

1977-1979 Tufts Medical Center: Cardiology Fellowship

1976 National Heart, Lung and Blood Institute: Individual Postdoctoral Research Fellowship in Cardiovascular Diseases

1976-1977 University Hospital (Boston Medical Center): Chief Medical Residency

1974-1976 University Hospital (Boston Medical Center): Medical Residency

1974 Alpha Omega Alpha Medical Honor Society

1969 National Jesuit Collegiate Honor Society: Alpha Sigma Nu

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Stable ischemic heart disease
Post-MI secondary prevention
Acute Coronary Syndromes
Preventive cardiology

Contact for Mentoring:

150 South Huntington Avenue
Boston MA 02130
Google Map

857.364.4201

Download vCard

Boden's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (604) concept(s)

Media Mentions

Co-Authors

See all (20) people

Similar People

See all (60) people

Same Department

Search Department